https://trial.medpath.com/news/alcon-s-advanced-clareon-panoptix-pro-iol-receives-canadian-approval-for-cataract-surgery 2025-07-10T16:24:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcon-s-advanced-clareon-panoptix-pro-iol-receives-canadian-approval-for-cataract-surgery 2025-07-10T16:24:19+00:00 hourly 0.9 https://trial.medpath.com/news/nuclidium-raises-99m-series-b-to-advance-copper-based-radiopharmaceutical-platform 2025-07-10T16:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclidium-raises-99m-series-b-to-advance-copper-based-radiopharmaceutical-platform 2025-07-10T16:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/arcus-biosciences-cd73-inhibitor-quemliclustat-receives-fda-orphan-drug-designation-for-pancreatic-cancer 2025-07-10T15:16:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcus-biosciences-cd73-inhibitor-quemliclustat-receives-fda-orphan-drug-designation-for-pancreatic-cancer 2025-07-10T15:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/radiant-biotherapeutics-appoints-deborah-geraghty-as-president-and-ceo 2025-07-10T15:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiant-biotherapeutics-appoints-deborah-geraghty-as-president-and-ceo 2025-07-10T15:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/florida-launches-first-in-nation-newborn-genetic-screening-program-with-7-5-million-state-investment 2025-07-10T15:13:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-launches-first-in-nation-newborn-genetic-screening-program-with-7-5-million-state-investment 2025-07-10T15:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/pds-biotech-s-novel-il-12-adc-advances-to-phase-2-stage-2-in-metastatic-colorectal-cancer 2025-07-10T12:56:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pds-biotech-s-novel-il-12-adc-advances-to-phase-2-stage-2-in-metastatic-colorectal-cancer 2025-07-10T12:56:30+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-pharma-supreme-court-petition-could-reshape-patent-obviousness-standards-for-pharmaceutical-industry 2025-07-10T12:55:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purdue-pharma-supreme-court-petition-could-reshape-patent-obviousness-standards-for-pharmaceutical-industry 2025-07-10T12:55:59+00:00 hourly 0.9 https://trial.medpath.com/news/nih-researchers-achieve-breakthrough-in-immunotherapy-for-metastatic-colon-cancer 2025-07-10T12:55:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-researchers-achieve-breakthrough-in-immunotherapy-for-metastatic-colon-cancer 2025-07-10T12:55:53+00:00 hourly 0.9 https://trial.medpath.com/news/epitopea-strengthens-leadership-team-as-rna-based-cancer-immunotherapy-platform-advances-toward-clinical-trials 2025-07-10T12:55:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epitopea-strengthens-leadership-team-as-rna-based-cancer-immunotherapy-platform-advances-toward-clinical-trials 2025-07-10T12:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-enables-mice-to-produce-diabetes-drug-exenatide-for-sustained-weight-control 2025-07-10T12:55:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-editing-enables-mice-to-produce-diabetes-drug-exenatide-for-sustained-weight-control 2025-07-10T12:55:29+00:00 hourly 0.9 https://trial.medpath.com/news/varda-space-industries-secures-187-million-series-c-to-advance-microgravity-drug-manufacturing 2025-07-10T12:55:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/varda-space-industries-secures-187-million-series-c-to-advance-microgravity-drug-manufacturing 2025-07-10T12:55:27+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-advances-long-term-amlitelimab-study-for-moderate-to-severe-atopic-dermatitis 2025-07-10T12:22:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-advances-long-term-amlitelimab-study-for-moderate-to-severe-atopic-dermatitis 2025-07-10T12:22:43+00:00 hourly 0.9 https://trial.medpath.com/news/medidata-expands-partnership-with-university-of-sydney-to-accelerate-clinical-trial-innovation 2025-07-10T12:22:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medidata-expands-partnership-with-university-of-sydney-to-accelerate-clinical-trial-innovation 2025-07-10T12:22:16+00:00 hourly 0.9 https://trial.medpath.com/news/tandemai-and-perpetual-medicines-merge-to-advance-ai-driven-small-molecule-and-peptide-drug-discovery 2025-07-10T12:22:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tandemai-and-perpetual-medicines-merge-to-advance-ai-driven-small-molecule-and-peptide-drug-discovery 2025-07-10T12:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/renasant-bio-raises-54-5m-to-develop-novel-ion-channel-therapies-for-adpkd 2025-07-10T12:20:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renasant-bio-raises-54-5m-to-develop-novel-ion-channel-therapies-for-adpkd 2025-07-10T12:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/renovaro-biosciences-converts-9-7m-debt-to-equity-strengthens-ai-driven-drug-discovery-platform 2025-07-10T12:19:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovaro-biosciences-converts-9-7m-debt-to-equity-strengthens-ai-driven-drug-discovery-platform 2025-07-10T12:19:55+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-s-biib080-receives-fda-fast-track-designation-for-alzheimer-s-disease-treatment 2025-07-10T10:19:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-s-biib080-receives-fda-fast-track-designation-for-alzheimer-s-disease-treatment 2025-07-10T10:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/cstone-pharmaceuticals-receives-nmpa-approval-for-local-manufacturing-of-ret-inhibitor-gavreto-in-china 2025-07-10T10:17:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cstone-pharmaceuticals-receives-nmpa-approval-for-local-manufacturing-of-ret-inhibitor-gavreto-in-china 2025-07-10T10:17:40+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-critical-gaps-in-lyme-disease-follow-up-care-and-diagnostic-testing 2025-07-10T10:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-critical-gaps-in-lyme-disease-follow-up-care-and-diagnostic-testing 2025-07-10T10:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/neurizon-receives-fda-approval-for-strategy-to-lift-clinical-hold-on-als-drug-nuz-001 2025-07-10T09:20:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurizon-receives-fda-approval-for-strategy-to-lift-clinical-hold-on-als-drug-nuz-001 2025-07-10T09:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/genomenon-and-ucb-partner-to-advance-thymidine-kinase-2-deficiency-diagnosis-through-genomic-intelligence 2025-07-10T09:18:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genomenon-and-ucb-partner-to-advance-thymidine-kinase-2-deficiency-diagnosis-through-genomic-intelligence 2025-07-10T09:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-driven-precision-medicine-transforms-treatment-landscape-for-metastatic-castration-sensitive-prostate-cancer 2025-07-10T09:18:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-driven-precision-medicine-transforms-treatment-landscape-for-metastatic-castration-sensitive-prostate-cancer 2025-07-10T09:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-completes-enrollment-for-keytruda-biosimilar-study-skips-phase-iii-trial-with-fda-approval 2025-07-10T08:18:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-completes-enrollment-for-keytruda-biosimilar-study-skips-phase-iii-trial-with-fda-approval 2025-07-10T08:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/new-non-opioid-painkiller-journavx-faces-access-barriers-despite-fda-approval 2025-07-10T04:59:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-non-opioid-painkiller-journavx-faces-access-barriers-despite-fda-approval 2025-07-10T04:59:18+00:00 hourly 0.9 https://trial.medpath.com/news/metabolic-signatures-predict-immunotherapy-response-in-metastatic-melanoma-patients 2025-07-10T04:58:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolic-signatures-predict-immunotherapy-response-in-metastatic-melanoma-patients 2025-07-10T04:58:52+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-gains-40-over-five-days-following-fda-ind-clearance-for-cell-therapy-program 2025-07-10T04:58:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caribou-biosciences-gains-40-over-five-days-following-fda-ind-clearance-for-cell-therapy-program 2025-07-10T04:58:42+00:00 hourly 0.9 https://trial.medpath.com/news/imagion-biosystems-receives-fda-fast-track-approval-for-magsense-her2-breast-cancer-imaging-agent 2025-07-10T04:58:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imagion-biosystems-receives-fda-fast-track-approval-for-magsense-her2-breast-cancer-imaging-agent 2025-07-10T04:58:30+00:00 hourly 0.9 https://trial.medpath.com/news/galectin-therapeutics-secures-10-million-credit-line-to-advance-mash-cirrhosis-program-through-2026 2025-07-10T03:23:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galectin-therapeutics-secures-10-million-credit-line-to-advance-mash-cirrhosis-program-through-2026 2025-07-10T03:23:21+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-pharmacists-expand-role-in-value-based-care-under-enhanced-oncology-model 2025-07-10T03:20:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-pharmacists-expand-role-in-value-based-care-under-enhanced-oncology-model 2025-07-10T03:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/longevity-biotechs-attract-4-8-billion-investment-as-companies-target-aging-mechanisms-over-life-extension 2025-07-10T03:19:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longevity-biotechs-attract-4-8-billion-investment-as-companies-target-aging-mechanisms-over-life-extension 2025-07-10T03:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/trump-announces-100-tariff-on-branded-pharmaceuticals-starting-october-1-exempts-companies-building-us-plants 2025-07-10T03:19:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-announces-100-tariff-on-branded-pharmaceuticals-starting-october-1-exempts-companies-building-us-plants 2025-07-10T03:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/progenra-discovers-first-in-class-pink1-activators-for-inherited-parkinson-s-disease 2025-07-10T02:20:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/progenra-discovers-first-in-class-pink1-activators-for-inherited-parkinson-s-disease 2025-07-10T02:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/prokidney-secures-fda-alignment-on-accelerated-approval-pathway-for-rilparencel-in-chronic-kidney-disease 2025-07-10T00:20:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prokidney-secures-fda-alignment-on-accelerated-approval-pathway-for-rilparencel-in-chronic-kidney-disease 2025-07-10T00:20:28+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-and-mereo-biopharma-advance-setrusumab-phase-3-studies-for-osteogenesis-imperfecta-toward-year-end-analysis 2025-07-10T00:19:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultragenyx-and-mereo-biopharma-advance-setrusumab-phase-3-studies-for-osteogenesis-imperfecta-toward-year-end-analysis 2025-07-10T00:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-therapeutics-initiates-phase-1-trial-of-novel-m4-receptor-modulator-nmra-861-for-schizophrenia 2025-07-09T22:17:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neumora-therapeutics-initiates-phase-1-trial-of-novel-m4-receptor-modulator-nmra-861-for-schizophrenia 2025-07-09T22:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/benitec-biopharma-advances-bb-301-gene-therapy-trial-for-opmd-following-positive-safety-review 2025-07-09T21:26:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benitec-biopharma-advances-bb-301-gene-therapy-trial-for-opmd-following-positive-safety-review 2025-07-09T21:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/geniphys-receives-fda-510-k-clearance-for-first-in-class-self-assembling-collagen-scaffold-for-wound-care 2025-07-09T21:24:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geniphys-receives-fda-510-k-clearance-for-first-in-class-self-assembling-collagen-scaffold-for-wound-care 2025-07-09T21:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/granules-india-recalls-33000-bottles-of-blood-pressure-medication-in-us-due-to-manufacturing-defects 2025-07-09T21:24:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/granules-india-recalls-33000-bottles-of-blood-pressure-medication-in-us-due-to-manufacturing-defects 2025-07-09T21:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/israeli-scientists-develop-first-mrna-vaccine-against-bacterial-infection-targeting-plague-pathogen 2025-07-09T21:21:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/israeli-scientists-develop-first-mrna-vaccine-against-bacterial-infection-targeting-plague-pathogen 2025-07-09T21:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-taiho-s-application-for-inqovi-venetoclax-combination-in-acute-myeloid-leukemia 2025-07-09T21:18:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-taiho-s-application-for-inqovi-venetoclax-combination-in-acute-myeloid-leukemia 2025-07-09T21:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-setmelanotide-shows-breakthrough-results-in-rare-hypothalamic-obesity-trial 2025-07-09T21:18:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-setmelanotide-shows-breakthrough-results-in-rare-hypothalamic-obesity-trial 2025-07-09T21:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/ofichem-group-acquires-avivia-to-expand-complex-formulation-development-capabilities 2025-07-09T20:24:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ofichem-group-acquires-avivia-to-expand-complex-formulation-development-capabilities 2025-07-09T20:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/xaira-therapeutics-appoints-jeff-jonker-as-president-and-coo-to-scale-ai-driven-drug-discovery-platform 2025-07-09T20:24:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xaira-therapeutics-appoints-jeff-jonker-as-president-and-coo-to-scale-ai-driven-drug-discovery-platform 2025-07-09T20:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-develop-ai-designed-protein-to-combat-antibiotic-resistant-e-coli 2025-07-09T20:24:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-researchers-develop-ai-designed-protein-to-combat-antibiotic-resistant-e-coli 2025-07-09T20:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/zhimeng-biopharma-s-cb03-154-receives-chinese-regulatory-approval-for-als-phase-2-3-trial 2025-07-09T20:23:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zhimeng-biopharma-s-cb03-154-receives-chinese-regulatory-approval-for-als-phase-2-3-trial 2025-07-09T20:23:04+00:00 hourly 0.9 https://trial.medpath.com/news/anthem-biosciences-positions-as-china-alternative-in-3-4-billion-ipo-amid-global-supply-chain-shift 2025-07-09T20:22:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anthem-biosciences-positions-as-china-alternative-in-3-4-billion-ipo-amid-global-supply-chain-shift 2025-07-09T20:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/kolon-tissuegene-expands-tg-c-cell-gene-therapy-to-spinal-indications-with-fda-approval 2025-07-09T20:19:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kolon-tissuegene-expands-tg-c-cell-gene-therapy-to-spinal-indications-with-fda-approval 2025-07-09T20:19:35+00:00 hourly 0.9 https://trial.medpath.com/news/beyondspring-s-plinabulin-shows-promise-in-reversing-immune-checkpoint-inhibitor-resistance-across-multiple-cancer-types 2025-07-09T19:17:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyondspring-s-plinabulin-shows-promise-in-reversing-immune-checkpoint-inhibitor-resistance-across-multiple-cancer-types 2025-07-09T19:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/empagliflozin-demonstrates-cost-effectiveness-in-chronic-kidney-disease-treatment-empa-kidney-analysis-shows 2025-07-09T19:17:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/empagliflozin-demonstrates-cost-effectiveness-in-chronic-kidney-disease-treatment-empa-kidney-analysis-shows 2025-07-09T19:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-s-tralokinumab-meets-all-endpoints-in-phase-3b-hand-atopic-dermatitis-trial 2025-07-09T18:22:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-s-tralokinumab-meets-all-endpoints-in-phase-3b-hand-atopic-dermatitis-trial 2025-07-09T18:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/mit-develops-implantable-device-for-automated-glucagon-delivery-to-prevent-diabetic-hypoglycemia 2025-07-09T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-develops-implantable-device-for-automated-glucagon-delivery-to-prevent-diabetic-hypoglycemia 2025-07-09T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-shows-promise-in-preventing-severe-morning-sickness-in-early-studies 2025-07-09T17:25:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-shows-promise-in-preventing-severe-morning-sickness-in-early-studies 2025-07-09T17:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-device-algorithm-detects-covid-19-infections-seven-days-earlier-than-symptom-based-screening 2025-07-09T17:24:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wearable-device-algorithm-detects-covid-19-infections-seven-days-earlier-than-symptom-based-screening 2025-07-09T17:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/sartorius-stedim-biotech-partners-with-sensible-biotechnologies-to-scale-cell-based-mrna-manufacturing-platform 2025-07-09T17:24:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sartorius-stedim-biotech-partners-with-sensible-biotechnologies-to-scale-cell-based-mrna-manufacturing-platform 2025-07-09T17:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/evoke-pharma-secures-patent-extension-for-gimoti-nasal-spray-extending-market-exclusivity-to-2036 2025-07-09T17:23:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evoke-pharma-secures-patent-extension-for-gimoti-nasal-spray-extending-market-exclusivity-to-2036 2025-07-09T17:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/celularity-partners-with-fountain-life-to-deploy-stem-cell-therapies-under-new-florida-law 2025-07-09T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celularity-partners-with-fountain-life-to-deploy-stem-cell-therapies-under-new-florida-law 2025-07-09T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/neuros-medical-secures-56-million-series-d-to-commercialize-fda-approved-post-amputation-pain-treatment 2025-07-09T17:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuros-medical-secures-56-million-series-d-to-commercialize-fda-approved-post-amputation-pain-treatment 2025-07-09T17:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-coq10-precursor-treatment-shows-dramatic-results-in-8-year-old-with-rare-fatal-disease 2025-07-09T16:29:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-coq10-precursor-treatment-shows-dramatic-results-in-8-year-old-with-rare-fatal-disease 2025-07-09T16:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-launches-primula-preg-study-to-evaluate-anifrolumab-safety-during-pregnancy-in-sle-patients 2025-07-09T16:29:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-launches-primula-preg-study-to-evaluate-anifrolumab-safety-during-pregnancy-in-sle-patients 2025-07-09T16:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-secures-exclusive-option-for-sironax-s-blood-brain-barrier-platform-in-175m-deal 2025-07-09T16:29:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-secures-exclusive-option-for-sironax-s-blood-brain-barrier-platform-in-175m-deal 2025-07-09T16:29:14+00:00 hourly 0.9 https://trial.medpath.com/news/kala-bio-completes-phase-2b-pced-trial-enrollment-no-fda-approved-options-exist 2025-07-09T16:29:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kala-bio-completes-phase-2b-pced-trial-enrollment-no-fda-approved-options-exist 2025-07-09T16:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/piper-sandler-initiates-overweight-rating-on-inovio-pharmaceuticals-ahead-of-potential-fda-approval-for-ino-3107 2025-07-09T16:29:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piper-sandler-initiates-overweight-rating-on-inovio-pharmaceuticals-ahead-of-potential-fda-approval-for-ino-3107 2025-07-09T16:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/four-company-consortium-launches-ai-driven-drug-discovery-for-subarachnoid-hemorrhage-complications 2025-07-09T16:27:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-company-consortium-launches-ai-driven-drug-discovery-for-subarachnoid-hemorrhage-complications 2025-07-09T16:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-partners-with-iambic-therapeutics-in-25m-ai-driven-drug-discovery-collaboration-for-ras-addicted-cancers 2025-07-09T16:27:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-partners-with-iambic-therapeutics-in-25m-ai-driven-drug-discovery-collaboration-for-ras-addicted-cancers 2025-07-09T16:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/exactech-receives-fda-clearance-for-first-to-market-scapula-reconstruction-system-targeting-post-surgical-fractures 2025-07-09T16:27:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exactech-receives-fda-clearance-for-first-to-market-scapula-reconstruction-system-targeting-post-surgical-fractures 2025-07-09T16:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/spt-labtech-and-semarion-partner-to-automate-cell-based-drug-screening-workflows 2025-07-09T16:27:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spt-labtech-and-semarion-partner-to-automate-cell-based-drug-screening-workflows 2025-07-09T16:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/uk-issues-class-2-recall-for-zaditen-eye-drops-batch-due-to-potential-microbial-contamination-risk 2025-07-09T16:26:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-issues-class-2-recall-for-zaditen-eye-drops-batch-due-to-potential-microbial-contamination-risk 2025-07-09T16:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/cingulate-appoints-chief-legal-officer-as-company-prepares-fda-filing-for-novel-adhd-treatment 2025-07-09T16:25:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cingulate-appoints-chief-legal-officer-as-company-prepares-fda-filing-for-novel-adhd-treatment 2025-07-09T16:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/suvoda-and-greenphire-complete-merger-to-create-integrated-clinical-trial-technology-platform 2025-07-09T16:24:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/suvoda-and-greenphire-complete-merger-to-create-integrated-clinical-trial-technology-platform 2025-07-09T16:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/salarius-pharmaceuticals-seclidemstat-gains-validation-as-lsd1-inhibitor-in-new-studies-while-phase-1-2-trial-advances 2025-07-09T14:18:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salarius-pharmaceuticals-seclidemstat-gains-validation-as-lsd1-inhibitor-in-new-studies-while-phase-1-2-trial-advances 2025-07-09T14:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-terminates-adc-platform-technology-contract-with-intussell-over-patent-concerns 2025-07-09T13:22:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abl-bio-terminates-adc-platform-technology-contract-with-intussell-over-patent-concerns 2025-07-09T13:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-two-il-23-inhibitors-for-crohn-s-disease-as-gastroenterology-advances-in-2025 2025-07-09T13:21:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-two-il-23-inhibitors-for-crohn-s-disease-as-gastroenterology-advances-in-2025 2025-07-09T13:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/nature-study-validates-lixte-s-pp2a-inhibitor-lb-100-for-enhanced-cancer-immunotherapy 2025-07-09T13:18:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-study-validates-lixte-s-pp2a-inhibitor-lb-100-for-enhanced-cancer-immunotherapy 2025-07-09T13:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-acquires-swiss-packaging-specialist-ivers-lee-to-expand-biosimilar-manufacturing-capacity 2025-07-09T13:17:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-acquires-swiss-packaging-specialist-ivers-lee-to-expand-biosimilar-manufacturing-capacity 2025-07-09T13:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-quietly-advances-marburg-and-sudan-ebolavirus-vaccine-development-despite-kennedy-s-vaccine-skepticism 2025-07-09T13:17:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-quietly-advances-marburg-and-sudan-ebolavirus-vaccine-development-despite-kennedy-s-vaccine-skepticism 2025-07-09T13:17:23+00:00 hourly 0.9 https://trial.medpath.com/news/mattel-launches-first-type-1-diabetes-barbie-doll-with-medical-device-accessories 2025-07-09T13:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mattel-launches-first-type-1-diabetes-barbie-doll-with-medical-device-accessories 2025-07-09T13:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/phesi-ceo-warns-of-impending-phase-3-trial-failures-due-to-site-oversaturation-and-complex-design 2025-07-09T12:14:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phesi-ceo-warns-of-impending-phase-3-trial-failures-due-to-site-oversaturation-and-complex-design 2025-07-09T12:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/centivax-secures-45-million-series-a-to-advance-universal-flu-vaccine-into-phase-i-clinical-trial 2025-07-09T08:55:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centivax-secures-45-million-series-a-to-advance-universal-flu-vaccine-into-phase-i-clinical-trial 2025-07-09T08:55:48+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-secures-50-million-licensing-deal-with-zentiva-for-global-certolizumab-pegol-biosimilar-rollout 2025-07-09T08:55:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-secures-50-million-licensing-deal-with-zentiva-for-global-certolizumab-pegol-biosimilar-rollout 2025-07-09T08:55:15+00:00 hourly 0.9 https://trial.medpath.com/news/dri-scientists-achieve-diabetes-reversal-using-small-peptide-thr-123-in-preclinical-models 2025-07-09T08:54:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dri-scientists-achieve-diabetes-reversal-using-small-peptide-thr-123-in-preclinical-models 2025-07-09T08:54:55+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-seeks-european-approval-to-expand-akeega-for-metastatic-prostate-cancer-with-genetic-alterations 2025-07-09T08:18:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-seeks-european-approval-to-expand-akeega-for-metastatic-prostate-cancer-with-genetic-alterations 2025-07-09T08:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-x-and-servier-launch-first-european-xseed-labs-to-advance-ai-driven-bispecific-antibody-design 2025-07-09T08:18:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomed-x-and-servier-launch-first-european-xseed-labs-to-advance-ai-driven-bispecific-antibody-design 2025-07-09T08:18:35+00:00 hourly 0.9 https://trial.medpath.com/news/merck-announces-10-billion-acquisition-of-verona-pharma-to-expand-copd-treatment-portfolio 2025-07-09T08:18:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-announces-10-billion-acquisition-of-verona-pharma-to-expand-copd-treatment-portfolio 2025-07-09T08:18:08+00:00 hourly 0.9 https://trial.medpath.com/news/nurexone-s-exopten-achieves-100-motor-function-recovery-in-spinal-cord-injury-preclinical-study 2025-07-09T07:17:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurexone-s-exopten-achieves-100-motor-function-recovery-in-spinal-cord-injury-preclinical-study 2025-07-09T07:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/aktiia-s-hilo-band-becomes-first-fda-cleared-cuffless-blood-pressure-monitor-for-over-the-counter-use 2025-07-09T05:19:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aktiia-s-hilo-band-becomes-first-fda-cleared-cuffless-blood-pressure-monitor-for-over-the-counter-use 2025-07-09T05:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/two-new-tuberculosis-drugs-show-superior-safety-profile-over-linezolid-in-phase-2b-trials 2025-07-09T05:19:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-new-tuberculosis-drugs-show-superior-safety-profile-over-linezolid-in-phase-2b-trials 2025-07-09T05:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-develops-dual-active-material-science-technology-for-glp-1-drug-protection 2025-07-09T04:20:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-develops-dual-active-material-science-technology-for-glp-1-drug-protection 2025-07-09T04:20:27+00:00 hourly 0.9 https://trial.medpath.com/news/bionxt-solutions-advances-targeted-chemotherapy-delivery-platform-to-enhance-precision-oncology 2025-07-09T04:20:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionxt-solutions-advances-targeted-chemotherapy-delivery-platform-to-enhance-precision-oncology 2025-07-09T04:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-testing-and-circulating-tumor-dna-advances-set-to-transform-gist-management 2025-07-09T03:18:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-testing-and-circulating-tumor-dna-advances-set-to-transform-gist-management 2025-07-09T03:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-meta-analysis-confirms-strong-association-between-alopecia-areata-and-multiple-immune-mediated-disorders 2025-07-09T03:17:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-meta-analysis-confirms-strong-association-between-alopecia-areata-and-multiple-immune-mediated-disorders 2025-07-09T03:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/medical-organizations-sue-rfk-jr-over-unlawful-covid-19-vaccine-policy-changes 2025-07-09T03:17:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-organizations-sue-rfk-jr-over-unlawful-covid-19-vaccine-policy-changes 2025-07-09T03:17:31+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-launches-varipulsetm-pulsed-field-ablation-platform-across-asia-pacific-for-atrial-fibrillation-treatment 2025-07-09T01:20:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-launches-varipulsetm-pulsed-field-ablation-platform-across-asia-pacific-for-atrial-fibrillation-treatment 2025-07-09T01:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/cresset-acquires-molab-ai-to-enhance-ai-driven-drug-discovery-platform 2025-07-09T01:20:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cresset-acquires-molab-ai-to-enhance-ai-driven-drug-discovery-platform 2025-07-09T01:20:16+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-wins-federal-circuit-appeal-preserves-invega-sustenna-patent-protection-until-2031 2025-07-09T01:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-wins-federal-circuit-appeal-preserves-invega-sustenna-patent-protection-until-2031 2025-07-09T01:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-appoints-chad-spooner-as-cfo-for-minimed-diabetes-spinoff 2025-07-09T00:18:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-appoints-chad-spooner-as-cfo-for-minimed-diabetes-spinoff 2025-07-09T00:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/adagene-partners-with-conjugatebio-to-develop-novel-bispecific-antibody-drug-conjugates 2025-07-09T00:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adagene-partners-with-conjugatebio-to-develop-novel-bispecific-antibody-drug-conjugates 2025-07-09T00:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/eye-net-achieves-99-detection-rate-in-french-urban-mobility-safety-trial 2025-07-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eye-net-achieves-99-detection-rate-in-french-urban-mobility-safety-trial 2025-07-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eluciderm-receives-fda-clearance-for-first-in-human-trial-of-elu42-in-diabetic-foot-ulcers 2025-07-08T23:17:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eluciderm-receives-fda-clearance-for-first-in-human-trial-of-elu42-in-diabetic-foot-ulcers 2025-07-08T23:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-submits-fda-application-to-expand-caplyta-for-schizophrenia-relapse-prevention 2025-07-08T21:20:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-submits-fda-application-to-expand-caplyta-for-schizophrenia-relapse-prevention 2025-07-08T21:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/prokidney-s-rilparencel-shows-promising-phase-2-results-for-diabetic-kidney-disease 2025-07-08T21:20:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prokidney-s-rilparencel-shows-promising-phase-2-results-for-diabetic-kidney-disease 2025-07-08T21:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/iric-and-ipsen-initiate-phase-1-trial-of-raf-inhibitor-ipn01195-for-solid-tumors 2025-07-08T21:20:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iric-and-ipsen-initiate-phase-1-trial-of-raf-inhibitor-ipn01195-for-solid-tumors 2025-07-08T21:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/dermata-therapeutics-secures-australian-patent-for-needle-free-botulinum-toxin-hyperhidrosis-treatment 2025-07-08T21:19:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dermata-therapeutics-secures-australian-patent-for-needle-free-botulinum-toxin-hyperhidrosis-treatment 2025-07-08T21:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/solid-biosciences-receives-fda-and-health-canada-approval-for-first-in-class-gene-therapy-targeting-fatal-heart-rhythm-disorder 2025-07-08T21:18:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solid-biosciences-receives-fda-and-health-canada-approval-for-first-in-class-gene-therapy-targeting-fatal-heart-rhythm-disorder 2025-07-08T21:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/georgia-tech-develops-exploding-capsule-technology-for-needle-free-insulin-delivery 2025-07-08T20:22:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/georgia-tech-develops-exploding-capsule-technology-for-needle-free-insulin-delivery 2025-07-08T20:22:40+00:00 hourly 0.9 https://trial.medpath.com/news/fziomed-receives-fda-de-novo-authorization-for-oxiplex-gel-in-lumbar-spine-surgery 2025-07-08T20:21:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fziomed-receives-fda-de-novo-authorization-for-oxiplex-gel-in-lumbar-spine-surgery 2025-07-08T20:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/cumulus-neuroscience-raises-ps3-25m-to-transform-neurological-clinical-trials-with-fda-cleared-eeg-technology 2025-07-08T20:20:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumulus-neuroscience-raises-ps3-25m-to-transform-neurological-clinical-trials-with-fda-cleared-eeg-technology 2025-07-08T20:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/nyb-ai-and-pnaseer-inc-form-strategic-partnership-to-advance-ai-powered-hair-regeneration-research 2025-07-08T20:20:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyb-ai-and-pnaseer-inc-form-strategic-partnership-to-advance-ai-powered-hair-regeneration-research 2025-07-08T20:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/stampede-trial-shows-metformin-improves-metabolic-health-in-metastatic-prostate-cancer-patients-despite-no-survival-benefit 2025-07-08T19:19:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stampede-trial-shows-metformin-improves-metabolic-health-in-metastatic-prostate-cancer-patients-despite-no-survival-benefit 2025-07-08T19:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/cardio-diagnostics-partners-with-agepha-pharma-to-validate-ai-powered-precision-medicine-approach-for-inflammation-driven-coronary-heart-disease 2025-07-08T17:37:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardio-diagnostics-partners-with-agepha-pharma-to-validate-ai-powered-precision-medicine-approach-for-inflammation-driven-coronary-heart-disease 2025-07-08T17:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-acquires-providence-digital-health-spinoff-xealth-to-bridge-consumer-wellness-and-clinical-care 2025-07-08T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-acquires-providence-digital-health-spinoff-xealth-to-bridge-consumer-wellness-and-clinical-care 2025-07-08T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/ciloa-secures-eur6-5-million-french-government-funding-to-advance-novel-adiponectin-based-therapy-for-obesity-and-type-2-diabetes 2025-07-08T17:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ciloa-secures-eur6-5-million-french-government-funding-to-advance-novel-adiponectin-based-therapy-for-obesity-and-type-2-diabetes 2025-07-08T17:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-healthcare-presents-real-world-data-on-long-acting-hiv-treatments-at-ias-2025 2025-07-08T17:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viiv-healthcare-presents-real-world-data-on-long-acting-hiv-treatments-at-ias-2025 2025-07-08T17:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/first-nanobody-treatment-shows-promise-against-deadly-nipah-and-hendra-viruses 2025-07-08T17:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-nanobody-treatment-shows-promise-against-deadly-nipah-and-hendra-viruses 2025-07-08T17:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/nobel-peace-prize-laureate-james-orbinski-joins-ai-drug-repurposing-startup-fifty-1-labs 2025-07-08T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nobel-peace-prize-laureate-james-orbinski-joins-ai-drug-repurposing-startup-fifty-1-labs 2025-07-08T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-secures-50-million-investment-to-expand-brain-cancer-clinical-trials-in-mena-region 2025-07-08T17:29:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-technologies-secures-50-million-investment-to-expand-brain-cancer-clinical-trials-in-mena-region 2025-07-08T17:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/bostongene-partners-with-swog-cancer-research-network-for-ai-driven-small-cell-lung-cancer-precision-medicine-trial 2025-07-08T17:29:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bostongene-partners-with-swog-cancer-research-network-for-ai-driven-small-cell-lung-cancer-precision-medicine-trial 2025-07-08T17:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/amarna-therapeutics-and-northx-biologics-advance-gene-therapy-for-type-1-diabetes-toward-clinical-trials 2025-07-08T17:27:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amarna-therapeutics-and-northx-biologics-advance-gene-therapy-for-type-1-diabetes-toward-clinical-trials 2025-07-08T17:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/concentra-biosciences-acquires-cargo-therapeutics-for-202m-following-car-t-trial-failure 2025-07-08T17:27:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concentra-biosciences-acquires-cargo-therapeutics-for-202m-following-car-t-trial-failure 2025-07-08T17:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/champions-oncology-launches-comprehensive-radiopharmaceutical-services-platform-with-expanded-isotope-capabilities 2025-07-08T17:27:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/champions-oncology-launches-comprehensive-radiopharmaceutical-services-platform-with-expanded-isotope-capabilities 2025-07-08T17:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-completes-akoya-biosciences-acquisition-creating-integrated-biomarker-detection-platform 2025-07-08T17:27:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanterix-completes-akoya-biosciences-acquisition-creating-integrated-biomarker-detection-platform 2025-07-08T17:27:23+00:00 hourly 0.9 https://trial.medpath.com/news/eib-provides-eur150-million-to-alfasigma-for-rare-disease-and-specialty-care-innovation 2025-07-08T17:27:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eib-provides-eur150-million-to-alfasigma-for-rare-disease-and-specialty-care-innovation 2025-07-08T17:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-acquires-full-rights-to-rev102-potential-first-in-class-oral-enpp1-inhibitor-for-hypophosphatasia 2025-07-08T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-pharmaceuticals-acquires-full-rights-to-rev102-potential-first-in-class-oral-enpp1-inhibitor-for-hypophosphatasia 2025-07-08T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/jcr-pharmaceuticals-licenses-just-aav-gene-therapy-platform-to-alexion-in-825-million-deal 2025-07-08T17:26:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jcr-pharmaceuticals-licenses-just-aav-gene-therapy-platform-to-alexion-in-825-million-deal 2025-07-08T17:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/certara-expands-clinical-technology-partnership-with-merck-to-streamline-data-management 2025-07-08T17:26:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/certara-expands-clinical-technology-partnership-with-merck-to-streamline-data-management 2025-07-08T17:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/mmj-international-advances-first-plant-based-cannabis-drug-mmj-001-for-huntington-s-disease-chorea 2025-07-08T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mmj-international-advances-first-plant-based-cannabis-drug-mmj-001-for-huntington-s-disease-chorea 2025-07-08T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/circular-genomics-secures-250k-addf-investment-to-advance-circrna-blood-biomarkers-for-alzheimer-s-diagnosis 2025-07-08T17:25:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circular-genomics-secures-250k-addf-investment-to-advance-circrna-blood-biomarkers-for-alzheimer-s-diagnosis 2025-07-08T17:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-appoints-dr-richard-philipson-as-chief-medical-officer-to-lead-next-development-phase 2025-07-08T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansa-biopharma-appoints-dr-richard-philipson-as-chief-medical-officer-to-lead-next-development-phase 2025-07-08T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/flightpath-biosciences-licenses-microbiome-sparing-antibiotic-lolamicin-for-gram-negative-bacterial-infections 2025-07-08T17:24:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flightpath-biosciences-licenses-microbiome-sparing-antibiotic-lolamicin-for-gram-negative-bacterial-infections 2025-07-08T17:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/australian-scientists-develop-proteus-biological-ai-platform-to-accelerate-drug-discovery 2025-07-08T17:23:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-scientists-develop-proteus-biological-ai-platform-to-accelerate-drug-discovery 2025-07-08T17:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-oncology-secures-10m-equity-agreement-to-advance-ai-driven-cancer-drug-discovery 2025-07-08T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictive-oncology-secures-10m-equity-agreement-to-advance-ai-driven-cancer-drug-discovery 2025-07-08T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/taiho-s-pizuglanstat-fails-to-meet-primary-endpoint-in-phase-iii-duchenne-muscular-dystrophy-trial 2025-07-08T16:20:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiho-s-pizuglanstat-fails-to-meet-primary-endpoint-in-phase-iii-duchenne-muscular-dystrophy-trial 2025-07-08T16:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/varmx-receives-fda-fast-track-designation-for-vmx-c001-anticoagulant-reversal-therapy 2025-07-08T16:19:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/varmx-receives-fda-fast-track-designation-for-vmx-c001-anticoagulant-reversal-therapy 2025-07-08T16:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/mendaera-s-focalist-handheld-robotic-system-receives-fda-clearance-for-ultrasound-guided-procedures 2025-07-08T16:19:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mendaera-s-focalist-handheld-robotic-system-receives-fda-clearance-for-ultrasound-guided-procedures 2025-07-08T16:19:47+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-validates-ai-powered-blood-test-for-multi-cancer-detection-and-monitoring 2025-07-08T16:19:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-validates-ai-powered-blood-test-for-multi-cancer-detection-and-monitoring 2025-07-08T16:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/insightec-receives-fda-approval-for-bilateral-focused-ultrasound-treatment-in-advanced-parkinson-s-disease 2025-07-08T16:17:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insightec-receives-fda-approval-for-bilateral-focused-ultrasound-treatment-in-advanced-parkinson-s-disease 2025-07-08T16:17:09+00:00 hourly 0.9 https://trial.medpath.com/news/verified-clinical-trials-launches-advanced-subject-registry-platform-in-japan-to-combat-duplicate-trial-participants 2025-07-08T16:16:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verified-clinical-trials-launches-advanced-subject-registry-platform-in-japan-to-combat-duplicate-trial-participants 2025-07-08T16:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/dual-payload-adcs-enter-clinical-testing-as-innovent-and-chengdu-kanghong-pioneer-next-generation-cancer-therapeutics 2025-07-08T16:16:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-payload-adcs-enter-clinical-testing-as-innovent-and-chengdu-kanghong-pioneer-next-generation-cancer-therapeutics 2025-07-08T16:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/anthem-biosciences-launches-3395-crore-ipo-as-contract-research-organization-targets-public-markets 2025-07-08T16:16:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anthem-biosciences-launches-3395-crore-ipo-as-contract-research-organization-targets-public-markets 2025-07-08T16:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/simcere-submits-new-drug-application-for-rademikibart-in-china-s-70-million-patient-atopic-dermatitis-market 2025-07-08T16:13:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simcere-submits-new-drug-application-for-rademikibart-in-china-s-70-million-patient-atopic-dermatitis-market 2025-07-08T16:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/sarilumab-combination-achieves-63-6-response-rate-in-advanced-melanoma-phase-2-trial 2025-07-08T15:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarilumab-combination-achieves-63-6-response-rate-in-advanced-melanoma-phase-2-trial 2025-07-08T15:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-pandemic-drove-sharp-rise-in-obesity-among-black-children-and-adolescents-study-finds 2025-07-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-pandemic-drove-sharp-rise-in-obesity-among-black-children-and-adolescents-study-finds 2025-07-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-submits-fda-application-for-caplyta-schizophrenia-relapse-prevention-based-on-63-risk-reduction-data 2025-07-08T12:56:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-submits-fda-application-for-caplyta-schizophrenia-relapse-prevention-based-on-63-risk-reduction-data 2025-07-08T12:56:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-emergency-compassionate-use-of-var-200-for-ultra-rare-apocii-amyloidosis 2025-07-08T12:55:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-emergency-compassionate-use-of-var-200-for-ultra-rare-apocii-amyloidosis 2025-07-08T12:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/crescent-biopharma-appoints-jan-pinkas-as-chief-scientific-officer-to-advance-oncology-pipeline 2025-07-08T12:54:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crescent-biopharma-appoints-jan-pinkas-as-chief-scientific-officer-to-advance-oncology-pipeline 2025-07-08T12:54:56+00:00 hourly 0.9 https://trial.medpath.com/news/optibrium-secures-multi-million-pound-financing-to-accelerate-ai-powered-drug-discovery-platform 2025-07-08T12:22:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optibrium-secures-multi-million-pound-financing-to-accelerate-ai-powered-drug-discovery-platform 2025-07-08T12:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/prokidney-s-rilparencel-shows-78-improvement-in-kidney-function-decline-in-phase-2-ckd-trial 2025-07-08T12:21:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prokidney-s-rilparencel-shows-78-improvement-in-kidney-function-decline-in-phase-2-ckd-trial 2025-07-08T12:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-briquilimab-shows-89-complete-response-rate-in-csu-despite-manufacturing-setbacks 2025-07-08T12:21:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jasper-therapeutics-briquilimab-shows-89-complete-response-rate-in-csu-despite-manufacturing-setbacks 2025-07-08T12:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/duke-street-bio-receives-fda-fast-track-designation-for-brain-penetrating-parp1-inhibitor-dsb2455 2025-07-08T12:20:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-street-bio-receives-fda-fast-track-designation-for-brain-penetrating-parp1-inhibitor-dsb2455 2025-07-08T12:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/veeda-lifesciences-partners-with-mango-sciences-to-deploy-ai-powered-platform-for-enhanced-clinical-trial-diversity 2025-07-08T12:19:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veeda-lifesciences-partners-with-mango-sciences-to-deploy-ai-powered-platform-for-enhanced-clinical-trial-diversity 2025-07-08T12:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-expands-fast-track-patent-program-to-20000-applications-annually-as-accelerated-examination-program-ends 2025-07-08T11:18:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uspto-expands-fast-track-patent-program-to-20000-applications-annually-as-accelerated-examination-program-ends 2025-07-08T11:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/morphic-medical-receives-ce-mark-for-reset-obesity-device-targeting-alternative-to-bariatric-surgery 2025-07-08T10:24:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/morphic-medical-receives-ce-mark-for-reset-obesity-device-targeting-alternative-to-bariatric-surgery 2025-07-08T10:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-secures-39-million-barda-funding-to-advance-novel-antifungal-candidates-fosmanogepix-and-bal2062 2025-07-08T09:19:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basilea-secures-39-million-barda-funding-to-advance-novel-antifungal-candidates-fosmanogepix-and-bal2062 2025-07-08T09:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/navamedic-expands-into-addiction-treatment-with-nok-225-million-acquisition-of-dne-pharma 2025-07-08T09:19:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navamedic-expands-into-addiction-treatment-with-nok-225-million-acquisition-of-dne-pharma 2025-07-08T09:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/biorce-secures-eur5m-to-transform-clinical-trials-with-ai-driven-platform 2025-07-08T09:18:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biorce-secures-eur5m-to-transform-clinical-trials-with-ai-driven-platform 2025-07-08T09:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/lobe-sciences-secures-european-patent-protection-for-dha-based-sickle-cell-disease-treatment 2025-07-08T09:18:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lobe-sciences-secures-european-patent-protection-for-dha-based-sickle-cell-disease-treatment 2025-07-08T09:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/corbion-gains-chinese-regulatory-approval-for-algae-derived-omega-3-dha-products 2025-07-08T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corbion-gains-chinese-regulatory-approval-for-algae-derived-omega-3-dha-products 2025-07-08T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-receives-approval-for-first-malaria-treatment-designed-for-newborns-and-young-infants 2025-07-08T08:12:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-receives-approval-for-first-malaria-treatment-designed-for-newborns-and-young-infants 2025-07-08T08:12:23+00:00 hourly 0.9 https://trial.medpath.com/news/kras-g12c-mutations-associated-with-shorter-survival-in-first-line-metastatic-colorectal-cancer-treatment 2025-07-08T08:11:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kras-g12c-mutations-associated-with-shorter-survival-in-first-line-metastatic-colorectal-cancer-treatment 2025-07-08T08:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/cero-therapeutics-advances-novel-cer-t-cell-therapy-for-aml-with-invivoscribe-diagnostic-support 2025-07-08T04:54:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cero-therapeutics-advances-novel-cer-t-cell-therapy-for-aml-with-invivoscribe-diagnostic-support 2025-07-08T04:54:23+00:00 hourly 0.9 https://trial.medpath.com/news/omass-therapeutics-to-present-first-preclinical-data-for-mc2-receptor-antagonist-oms1620-at-endo-2025 2025-07-08T03:20:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omass-therapeutics-to-present-first-preclinical-data-for-mc2-receptor-antagonist-oms1620-at-endo-2025 2025-07-08T03:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/sharp-clinical-launches-cdmo-podcast-series-to-address-drug-development-challenges 2025-07-08T03:16:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sharp-clinical-launches-cdmo-podcast-series-to-address-drug-development-challenges 2025-07-08T03:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-receives-10-million-milestone-payment-from-cttq-for-mash-drug-development-partnership 2025-07-08T01:17:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inventiva-receives-10-million-milestone-payment-from-cttq-for-mash-drug-development-partnership 2025-07-08T01:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/medmira-launches-clinical-trial-for-dual-hiv-syphilis-self-test-in-canada 2025-07-08T01:16:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medmira-launches-clinical-trial-for-dual-hiv-syphilis-self-test-in-canada 2025-07-08T01:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/abcellera-advances-two-first-in-class-antibody-therapies-to-phase-1-trials-following-strategic-pivot 2025-07-08T01:15:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abcellera-advances-two-first-in-class-antibody-therapies-to-phase-1-trials-following-strategic-pivot 2025-07-08T01:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-strengthens-leadership-team-with-new-cfo-and-senior-vp-appointments 2025-07-08T01:15:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascentage-pharma-strengthens-leadership-team-with-new-cfo-and-senior-vp-appointments 2025-07-08T01:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-xolair-biosimilar-omlyclo-for-allergic-diseases-marking-milestone-in-allergy-treatment-access 2025-07-08T01:15:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-xolair-biosimilar-omlyclo-for-allergic-diseases-marking-milestone-in-allergy-treatment-access 2025-07-08T01:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/yiv-906-shows-promising-results-in-phase-2b-trial-for-advanced-hepatocellular-carcinoma-with-hepatitis-b 2025-07-07T23:15:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yiv-906-shows-promising-results-in-phase-2b-trial-for-advanced-hepatocellular-carcinoma-with-hepatitis-b 2025-07-07T23:15:15+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-s-art12-11-cocrystal-shows-superior-antidepressant-effects-over-leading-ssri-in-preclinical-study 2025-07-07T22:18:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artelo-s-art12-11-cocrystal-shows-superior-antidepressant-effects-over-leading-ssri-in-preclinical-study 2025-07-07T22:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/nanobiotix-secures-eu-regulatory-harmonization-and-new-patent-for-cancer-radioenhancer-jnj-1900 2025-07-07T21:18:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanobiotix-secures-eu-regulatory-harmonization-and-new-patent-for-cancer-radioenhancer-jnj-1900 2025-07-07T21:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-covid-19-vaccines-show-superior-mucosal-immunity-and-long-term-protection-in-preclinical-studies 2025-07-07T21:18:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intranasal-covid-19-vaccines-show-superior-mucosal-immunity-and-long-term-protection-in-preclinical-studies 2025-07-07T21:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/insurance-disparities-widen-cancer-survival-gaps-despite-immune-checkpoint-inhibitor-advances 2025-07-07T21:17:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insurance-disparities-widen-cancer-survival-gaps-despite-immune-checkpoint-inhibitor-advances 2025-07-07T21:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/pd-l1-expression-correlates-with-hrd-status-and-predicts-survival-in-high-grade-serous-ovarian-cancer 2025-07-07T21:17:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pd-l1-expression-correlates-with-hrd-status-and-predicts-survival-in-high-grade-serous-ovarian-cancer 2025-07-07T21:17:10+00:00 hourly 0.9 https://trial.medpath.com/news/aspivix-launches-mhra-approved-carevix-cervical-stabilizer-in-uk-demonstrating-73-pain-reduction-in-iud-procedures 2025-07-07T21:15:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspivix-launches-mhra-approved-carevix-cervical-stabilizer-in-uk-demonstrating-73-pain-reduction-in-iud-procedures 2025-07-07T21:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/blue-lake-and-cyanvac-report-promising-phase-1-results-for-intranasal-covid-19-vaccine-cvxga 2025-07-07T20:18:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blue-lake-and-cyanvac-report-promising-phase-1-results-for-intranasal-covid-19-vaccine-cvxga 2025-07-07T20:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-study-reveals-liver-safety-concerns-with-low-dose-cbd-in-5-of-healthy-adults 2025-07-07T20:16:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-study-reveals-liver-safety-concerns-with-low-dose-cbd-in-5-of-healthy-adults 2025-07-07T20:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/venture-medical-leads-eur6-million-investment-in-cold-plasma-wound-therapy-developer-plasmacure 2025-07-07T18:17:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/venture-medical-leads-eur6-million-investment-in-cold-plasma-wound-therapy-developer-plasmacure 2025-07-07T18:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/panther-therapeutics-initiates-phase-1b-trial-of-novel-localized-chemotherapy-film-for-pancreatic-cancer 2025-07-07T17:14:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panther-therapeutics-initiates-phase-1b-trial-of-novel-localized-chemotherapy-film-for-pancreatic-cancer 2025-07-07T17:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/italy-appoints-special-commissioner-to-fast-track-novo-nordisk-s-2-3-billion-manufacturing-investment 2025-07-07T17:13:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/italy-appoints-special-commissioner-to-fast-track-novo-nordisk-s-2-3-billion-manufacturing-investment 2025-07-07T17:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/beyondspring-s-plinabulin-shows-promise-in-reversing-checkpoint-inhibitor-resistance-through-dendritic-cell-activation 2025-07-07T17:13:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyondspring-s-plinabulin-shows-promise-in-reversing-checkpoint-inhibitor-resistance-through-dendritic-cell-activation 2025-07-07T17:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-key-resistance-mechanism-to-cdk4-6-inhibitors-in-hr-her2-breast-cancer 2025-07-07T16:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-key-resistance-mechanism-to-cdk4-6-inhibitors-in-hr-her2-breast-cancer 2025-07-07T16:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/corticosteroids-identified-as-major-factor-limiting-immunotherapy-effectiveness-in-lung-cancer 2025-07-07T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corticosteroids-identified-as-major-factor-limiting-immunotherapy-effectiveness-in-lung-cancer 2025-07-07T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/maplight-therapeutics-initiates-phase-2-trial-of-novel-m1-m4-muscarinic-agonist-ml-007c-ma-for-schizophrenia-treatment 2025-07-07T16:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maplight-therapeutics-initiates-phase-2-trial-of-novel-m1-m4-muscarinic-agonist-ml-007c-ma-for-schizophrenia-treatment 2025-07-07T16:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-s-ff-10832-receives-fda-orphan-drug-designation-for-biliary-tract-cancer-treatment 2025-07-07T16:33:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujifilm-s-ff-10832-receives-fda-orphan-drug-designation-for-biliary-tract-cancer-treatment 2025-07-07T16:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/alcon-acquires-lumithera-s-photobiomodulation-device-for-dry-amd-treatment 2025-07-07T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcon-acquires-lumithera-s-photobiomodulation-device-for-dry-amd-treatment 2025-07-07T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/pace-life-sciences-expands-salem-facility-with-new-aseptic-fill-finish-center-of-excellence 2025-07-07T16:30:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pace-life-sciences-expands-salem-facility-with-new-aseptic-fill-finish-center-of-excellence 2025-07-07T16:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/heartbeat-bio-and-biotx-ai-partner-to-accelerate-heart-failure-drug-discovery-using-ai-and-human-cardiac-organoids 2025-07-07T16:26:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heartbeat-bio-and-biotx-ai-partner-to-accelerate-heart-failure-drug-discovery-using-ai-and-human-cardiac-organoids 2025-07-07T16:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/synfini-secures-8-9-million-to-accelerate-ai-driven-small-molecule-drug-discovery-platform 2025-07-07T16:26:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synfini-secures-8-9-million-to-accelerate-ai-driven-small-molecule-drug-discovery-platform 2025-07-07T16:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/restore-medical-secures-23m-series-b-to-advance-transcatheter-heart-failure-device-following-fda-breakthrough-designation 2025-07-07T16:24:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/restore-medical-secures-23m-series-b-to-advance-transcatheter-heart-failure-device-following-fda-breakthrough-designation 2025-07-07T16:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/sirtex-medical-s-sir-spheres-y-90-resin-microspheres-receive-fda-approval-for-unresectable-hepatocellular-carcinoma 2025-07-07T16:23:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirtex-medical-s-sir-spheres-y-90-resin-microspheres-receive-fda-approval-for-unresectable-hepatocellular-carcinoma 2025-07-07T16:23:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-mustang-bio-s-mb-101-car-t-therapy-for-brain-cancer-treatment 2025-07-07T16:23:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-mustang-bio-s-mb-101-car-t-therapy-for-brain-cancer-treatment 2025-07-07T16:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/bezuclastinib-achieves-87-response-rate-in-pivotal-trial-for-non-advanced-systemic-mastocytosis 2025-07-07T16:22:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bezuclastinib-achieves-87-response-rate-in-pivotal-trial-for-non-advanced-systemic-mastocytosis 2025-07-07T16:22:49+00:00 hourly 0.9 https://trial.medpath.com/news/orchard-therapeutics-completes-enrollment-in-pivotal-gene-therapy-trial-for-hurler-syndrome 2025-07-07T16:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orchard-therapeutics-completes-enrollment-in-pivotal-gene-therapy-trial-for-hurler-syndrome 2025-07-07T16:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/biosapien-secures-8-million-in-extended-pre-series-a-round-for-revolutionary-cancer-treatment-platform 2025-07-07T16:12:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosapien-secures-8-million-in-extended-pre-series-a-round-for-revolutionary-cancer-treatment-platform 2025-07-07T16:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytic-virus-immune-checkpoint-inhibitor-combinations-show-promise-in-melanoma-treatment 2025-07-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncolytic-virus-immune-checkpoint-inhibitor-combinations-show-promise-in-melanoma-treatment 2025-07-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phytogaia-s-tocotrienol-supplement-shows-promise-for-healthy-aging-in-clinical-trial 2025-07-07T15:13:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phytogaia-s-tocotrienol-supplement-shows-promise-for-healthy-aging-in-clinical-trial 2025-07-07T15:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/scottish-health-authority-approves-theramex-s-abaloparatide-for-high-risk-osteoporosis-treatment 2025-07-07T13:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scottish-health-authority-approves-theramex-s-abaloparatide-for-high-risk-osteoporosis-treatment 2025-07-07T13:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-pharmaceuticals-appoints-babar-ghias-as-cfo-and-head-of-corporate-development 2025-07-07T13:03:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocryst-pharmaceuticals-appoints-babar-ghias-as-cfo-and-head-of-corporate-development 2025-07-07T13:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/pakistan-approves-chinese-biosimilar-cancer-drug-to-expand-access-to-affordable-bevacizumab-treatment 2025-07-07T13:03:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pakistan-approves-chinese-biosimilar-cancer-drug-to-expand-access-to-affordable-bevacizumab-treatment 2025-07-07T13:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/biosynth-opens-expanded-gmp-bioconjugation-facility-in-berlin-to-support-next-generation-therapeutics 2025-07-07T13:02:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosynth-opens-expanded-gmp-bioconjugation-facility-in-berlin-to-support-next-generation-therapeutics 2025-07-07T13:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-and-gero-form-250m-partnership-to-develop-ai-driven-antibody-therapies-for-age-related-diseases 2025-07-07T13:02:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-and-gero-form-250m-partnership-to-develop-ai-driven-antibody-therapies-for-age-related-diseases 2025-07-07T13:02:16+00:00 hourly 0.9 https://trial.medpath.com/news/als-community-files-citizens-petition-seeking-fda-approval-for-nurown-stem-cell-therapy 2025-07-07T13:01:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/als-community-files-citizens-petition-seeking-fda-approval-for-nurown-stem-cell-therapy 2025-07-07T13:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/corflow-therapeutics-receives-fda-approval-for-moca-ii-pivotal-trial-testing-novel-heart-attack-diagnostic-technology 2025-07-07T13:00:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corflow-therapeutics-receives-fda-approval-for-moca-ii-pivotal-trial-testing-novel-heart-attack-diagnostic-technology 2025-07-07T13:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/eleva-advances-factor-h-therapy-cpv-104-into-first-in-human-trial-for-rare-kidney-disease-c3-glomerulopathy 2025-07-07T09:26:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eleva-advances-factor-h-therapy-cpv-104-into-first-in-human-trial-for-rare-kidney-disease-c3-glomerulopathy 2025-07-07T09:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-implements-capa-at-halol-facility-while-addressing-usfda-compliance-issues-across-three-manufacturing-sites 2025-07-07T09:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-implements-capa-at-halol-facility-while-addressing-usfda-compliance-issues-across-three-manufacturing-sites 2025-07-07T09:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/pulsesight-therapeutics-doses-first-patient-in-phase-i-trial-of-pst-611-for-dry-amd 2025-07-07T08:16:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulsesight-therapeutics-doses-first-patient-in-phase-i-trial-of-pst-611-for-dry-amd 2025-07-07T08:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/liquid-fat-supplement-shows-promise-in-treating-rare-childhood-disease-ataxia-telangiectasia 2025-07-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquid-fat-supplement-shows-promise-in-treating-rare-childhood-disease-ataxia-telangiectasia 2025-07-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amicus-therapeutics-secures-japan-approval-for-pombiliti-opfolda-combination-therapy-for-late-onset-pompe-disease 2025-07-06T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amicus-therapeutics-secures-japan-approval-for-pombiliti-opfolda-combination-therapy-for-late-onset-pompe-disease 2025-07-06T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-review-reveals-therapeutic-potential-of-m6a-regulatory-protein-inhibitors-in-cancer-treatment 2025-07-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-review-reveals-therapeutic-potential-of-m6a-regulatory-protein-inhibitors-in-cancer-treatment 2025-07-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/emcure-pharmaceuticals-acquires-full-control-of-zuventus-healthcare-in-724-9-crore-deal 2025-07-06T14:21:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emcure-pharmaceuticals-acquires-full-control-of-zuventus-healthcare-in-724-9-crore-deal 2025-07-06T14:21:55+00:00 hourly 0.9 https://trial.medpath.com/news/thailand-achieves-pharmaceutical-independence-with-first-domestically-produced-targeted-cancer-drugs 2025-07-06T13:22:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thailand-achieves-pharmaceutical-independence-with-first-domestically-produced-targeted-cancer-drugs 2025-07-06T13:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-expert-committee-accepts-pfizer-s-phase-iii-data-for-abrocitinib-in-atopic-dermatitis 2025-07-06T13:22:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-expert-committee-accepts-pfizer-s-phase-iii-data-for-abrocitinib-in-atopic-dermatitis 2025-07-06T13:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/drdo-and-aiims-rishikesh-partner-for-clinical-trials-of-biomedical-devices-in-extreme-environments 2025-07-06T13:21:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drdo-and-aiims-rishikesh-partner-for-clinical-trials-of-biomedical-devices-in-extreme-environments 2025-07-06T13:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-and-loxo-oncology-advance-phase-3-trial-testing-pirtobrutinib-combination-for-previously-treated-cll-sll 2025-07-06T00:58:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-and-loxo-oncology-advance-phase-3-trial-testing-pirtobrutinib-combination-for-previously-treated-cll-sll 2025-07-06T00:58:08+00:00 hourly 0.9 https://trial.medpath.com/news/andhra-pradesh-establishes-first-cdsco-notified-medical-device-auditing-body-to-streamline-regulatory-compliance 2025-07-06T00:16:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andhra-pradesh-establishes-first-cdsco-notified-medical-device-auditing-body-to-streamline-regulatory-compliance 2025-07-06T00:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-prepares-european-launch-of-subcutaneous-infliximab-biosimilar-following-positive-regulatory-opinion 2025-07-05T20:40:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-prepares-european-launch-of-subcutaneous-infliximab-biosimilar-following-positive-regulatory-opinion 2025-07-05T20:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-partners-with-children-s-national-hospital-to-advance-pediatric-cell-and-gene-therapy 2025-07-05T09:39:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abu-dhabi-partners-with-children-s-national-hospital-to-advance-pediatric-cell-and-gene-therapy 2025-07-05T09:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-medical-advances-pmx-hemoperfusion-device-toward-fda-approval-for-septic-shock-treatment 2025-07-05T09:38:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spectral-medical-advances-pmx-hemoperfusion-device-toward-fda-approval-for-septic-shock-treatment 2025-07-05T09:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/viemed-healthcare-completes-28m-acquisition-of-lehan-s-medical-equipment-to-expand-respiratory-care-services 2025-07-05T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viemed-healthcare-completes-28m-acquisition-of-lehan-s-medical-equipment-to-expand-respiratory-care-services 2025-07-05T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-advances-multiple-phase-2-trials-targeting-rare-kidney-diseases-and-ulcerative-colitis 2025-07-05T05:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-advances-multiple-phase-2-trials-targeting-rare-kidney-diseases-and-ulcerative-colitis 2025-07-05T05:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/btk-inhibitors-show-promise-for-progressive-ms-as-current-therapies-fall-short 2025-07-05T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/btk-inhibitors-show-promise-for-progressive-ms-as-current-therapies-fall-short 2025-07-05T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-launches-long-term-safety-study-for-tzield-in-stage-2-type-1-diabetes-patients 2025-07-05T00:40:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-launches-long-term-safety-study-for-tzield-in-stage-2-type-1-diabetes-patients 2025-07-05T00:40:32+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-biopharma-raises-75-million-to-advance-firmonertinib-and-cancer-pipeline 2025-07-05T00:38:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrivent-biopharma-raises-75-million-to-advance-firmonertinib-and-cancer-pipeline 2025-07-05T00:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/gallant-raises-18m-to-develop-first-fda-approved-off-the-shelf-stem-cell-therapy-for-pets 2025-07-05T00:38:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gallant-raises-18m-to-develop-first-fda-approved-off-the-shelf-stem-cell-therapy-for-pets 2025-07-05T00:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/mcmaster-s-inhaled-covid-19-vaccine-shows-promise-in-phase-1-trials-advances-to-phase-2 2025-07-04T22:02:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mcmaster-s-inhaled-covid-19-vaccine-shows-promise-in-phase-1-trials-advances-to-phase-2 2025-07-04T22:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/steep-hill-terminates-acquisition-of-obesity-focused-biotech-lir-life-sciences 2025-07-04T22:01:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/steep-hill-terminates-acquisition-of-obesity-focused-biotech-lir-life-sciences 2025-07-04T22:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/first-human-trial-of-regenerative-cell-therapy-for-sensorineural-hearing-loss-receives-uk-approval 2025-07-04T22:00:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-human-trial-of-regenerative-cell-therapy-for-sensorineural-hearing-loss-receives-uk-approval 2025-07-04T22:00:37+00:00 hourly 0.9 https://trial.medpath.com/news/first-us-nasal-covid-19-vaccine-shows-67-infection-reduction-in-phase-1-trial 2025-07-04T20:12:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-us-nasal-covid-19-vaccine-shows-67-infection-reduction-in-phase-1-trial 2025-07-04T20:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-medical-files-100-million-shelf-prospectus-ahead-of-septic-shock-treatment-milestones 2025-07-04T20:12:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spectral-medical-files-100-million-shelf-prospectus-ahead-of-septic-shock-treatment-milestones 2025-07-04T20:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-launches-generic-ipratropium-bromide-nasal-spray-in-us-market 2025-07-04T20:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-launches-generic-ipratropium-bromide-nasal-spray-in-us-market 2025-07-04T20:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-pharma-lifesciences-unit-1-passes-brazilian-anvisa-gmp-inspection-with-no-critical-findings 2025-07-04T17:54:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-pharma-lifesciences-unit-1-passes-brazilian-anvisa-gmp-inspection-with-no-critical-findings 2025-07-04T17:54:09+00:00 hourly 0.9 https://trial.medpath.com/news/particle-dynamics-acquires-euroapi-uk-spray-drying-facility-to-expand-global-cdmo-capabilities 2025-07-04T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/particle-dynamics-acquires-euroapi-uk-spray-drying-facility-to-expand-global-cdmo-capabilities 2025-07-04T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/precisio-biotix-achieves-first-in-human-dosing-of-clyo-lysin-for-multi-drug-resistant-prosthetic-joint-infection 2025-07-04T14:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precisio-biotix-achieves-first-in-human-dosing-of-clyo-lysin-for-multi-drug-resistant-prosthetic-joint-infection 2025-07-04T14:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/serendipity-space-secures-pre-seed-funding-to-advance-microgravity-based-pharmaceutical-manufacturing 2025-07-04T12:40:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serendipity-space-secures-pre-seed-funding-to-advance-microgravity-based-pharmaceutical-manufacturing 2025-07-04T12:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-for-fabry-disease-shows-promise-with-3-7-million-cost-savings-in-early-stage-trial 2025-07-04T12:38:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-for-fabry-disease-shows-promise-with-3-7-million-cost-savings-in-early-stage-trial 2025-07-04T12:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/spineway-secures-gmed-approval-for-new-esp-prostheses-production-line-doubles-manufacturing-capacity 2025-07-04T10:54:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spineway-secures-gmed-approval-for-new-esp-prostheses-production-line-doubles-manufacturing-capacity 2025-07-04T10:54:42+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nasal-antibody-treatment-shows-promise-for-hay-fever-prevention-in-preclinical-study 2025-07-04T09:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nasal-antibody-treatment-shows-promise-for-hay-fever-prevention-in-preclinical-study 2025-07-04T09:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-advances-ai-powered-mrna-platform-with-cancer-vaccine-breakthroughs 2025-07-04T09:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-advances-ai-powered-mrna-platform-with-cancer-vaccine-breakthroughs 2025-07-04T09:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-s-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer 2025-07-04T09:02:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ab-science-s-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer 2025-07-04T09:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/shimadzu-receives-fda-clearance-for-high-resolution-positview-pet-system-for-alzheimer-s-diagnosis 2025-07-04T08:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shimadzu-receives-fda-clearance-for-high-resolution-positview-pet-system-for-alzheimer-s-diagnosis 2025-07-04T08:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/lunit-partners-with-microsoft-to-develop-ai-powered-cancer-diagnostic-tools-on-azure-platform 2025-07-04T06:36:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunit-partners-with-microsoft-to-develop-ai-powered-cancer-diagnostic-tools-on-azure-platform 2025-07-04T06:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/bioatla-s-ba3182-shows-tumor-shrinkage-across-multiple-cancer-types-in-phase-1-trial 2025-07-04T06:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioatla-s-ba3182-shows-tumor-shrinkage-across-multiple-cancer-types-in-phase-1-trial 2025-07-04T06:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-secures-au-5-87-million-r-d-tax-refund-to-advance-immuno-oncology-pipeline 2025-07-04T06:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imugene-secures-au-5-87-million-r-d-tax-refund-to-advance-immuno-oncology-pipeline 2025-07-04T06:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/brii-biosciences-licenses-novel-antibiotic-brii-693-to-joincare-group-for-greater-china-market 2025-07-04T06:29:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brii-biosciences-licenses-novel-antibiotic-brii-693-to-joincare-group-for-greater-china-market 2025-07-04T06:29:16+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-s-casgevy-shows-sustained-efficacy-in-long-term-follow-up-data-for-sickle-cell-disease-and-beta-thalassemia 2025-07-04T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-s-casgevy-shows-sustained-efficacy-in-long-term-follow-up-data-for-sickle-cell-disease-and-beta-thalassemia 2025-07-04T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/editas-medicine-achieves-90-ldl-cholesterol-reduction-with-edit-401-gene-therapy-in-preclinical-studies 2025-07-04T06:18:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/editas-medicine-achieves-90-ldl-cholesterol-reduction-with-edit-401-gene-therapy-in-preclinical-studies 2025-07-04T06:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-advances-sacituzumab-govitecan-studies-across-multiple-cancer-types 2025-07-04T06:18:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-sciences-advances-sacituzumab-govitecan-studies-across-multiple-cancer-types 2025-07-04T06:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-s-lanifibranor-shows-promise-in-reversing-liver-vascular-damage-in-mash-patients 2025-07-04T06:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inventiva-s-lanifibranor-shows-promise-in-reversing-liver-vascular-damage-in-mash-patients 2025-07-04T06:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/godavari-biorefineries-secures-european-patent-for-novel-anticancer-molecule-targeting-cancer-stem-cells 2025-07-04T05:56:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/godavari-biorefineries-secures-european-patent-for-novel-anticancer-molecule-targeting-cancer-stem-cells 2025-07-04T05:56:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-thermo-fisher-s-rapid-ngs-companion-diagnostic-for-zegfrovy-in-nsclc 2025-07-04T05:54:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-thermo-fisher-s-rapid-ngs-companion-diagnostic-for-zegfrovy-in-nsclc 2025-07-04T05:54:50+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-s-ai-powered-discovery-engine-expands-molecular-glue-degrader-target-space-in-science-publication 2025-07-04T05:53:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monte-rosa-s-ai-powered-discovery-engine-expands-molecular-glue-degrader-target-space-in-science-publication 2025-07-04T05:53:10+00:00 hourly 0.9 https://trial.medpath.com/news/fluorescent-drug-bevonescein-shows-promise-for-nerve-sparing-surgery-in-phase-1-2-trial 2025-07-04T05:52:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fluorescent-drug-bevonescein-shows-promise-for-nerve-sparing-surgery-in-phase-1-2-trial 2025-07-04T05:52:25+00:00 hourly 0.9 https://trial.medpath.com/news/ebenbuild-secures-eur2-3-million-eic-grant-to-advance-digital-twin-platform-for-respiratory-drug-development 2025-07-04T05:47:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ebenbuild-secures-eur2-3-million-eic-grant-to-advance-digital-twin-platform-for-respiratory-drug-development 2025-07-04T05:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-acquires-utility-therapeutics-to-commercialize-first-new-uti-antibiotic-in-20-years 2025-07-04T05:46:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-acquires-utility-therapeutics-to-commercialize-first-new-uti-antibiotic-in-20-years 2025-07-04T05:46:13+00:00 hourly 0.9 https://trial.medpath.com/news/quebec-expands-public-reimbursement-of-pluvicto-radioligand-therapy-for-advanced-prostate-cancer 2025-07-04T05:35:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quebec-expands-public-reimbursement-of-pluvicto-radioligand-therapy-for-advanced-prostate-cancer 2025-07-04T05:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-summit-therapeutics-in-advanced-talks-for-15-billion-ivonescimab-licensing-deal 2025-07-04T05:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-and-summit-therapeutics-in-advanced-talks-for-15-billion-ivonescimab-licensing-deal 2025-07-04T05:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/mira-s-non-psychoactive-cannabis-analog-mira-55-matches-morphine-s-pain-relief-without-opioid-risks-in-preclinical-study 2025-07-04T05:22:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mira-s-non-psychoactive-cannabis-analog-mira-55-matches-morphine-s-pain-relief-without-opioid-risks-in-preclinical-study 2025-07-04T05:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/stallergenes-greer-transitions-actair-r-promotional-activities-from-shionogi-to-ceolia-in-japan 2025-07-04T05:17:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stallergenes-greer-transitions-actair-r-promotional-activities-from-shionogi-to-ceolia-in-japan 2025-07-04T05:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/eqt-healthcare-growth-acquires-europa-biosite-to-expand-life-sciences-distribution-network 2025-07-04T05:15:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eqt-healthcare-growth-acquires-europa-biosite-to-expand-life-sciences-distribution-network 2025-07-04T05:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/stereotaxis-magic-catheter-demonstrates-94-acute-efficacy-in-first-in-human-cardiac-ablation-study 2025-07-04T05:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stereotaxis-magic-catheter-demonstrates-94-acute-efficacy-in-first-in-human-cardiac-ablation-study 2025-07-04T05:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/iqure-pharma-appoints-former-ucb-chief-medical-officer-iris-loew-friedrich-as-clinical-and-r-d-advisor 2025-07-04T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqure-pharma-appoints-former-ucb-chief-medical-officer-iris-loew-friedrich-as-clinical-and-r-d-advisor 2025-07-04T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/rdp-pharma-and-singapore-s-eddc-partner-to-develop-protein-degrader-therapies-for-autoimmune-diseases 2025-07-04T05:03:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rdp-pharma-and-singapore-s-eddc-partner-to-develop-protein-degrader-therapies-for-autoimmune-diseases 2025-07-04T05:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biotherapeutics-and-boehringer-ingelheim-advance-third-oncology-drug-candidate-to-ind-enabling-studies 2025-07-04T04:55:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-biotherapeutics-and-boehringer-ingelheim-advance-third-oncology-drug-candidate-to-ind-enabling-studies 2025-07-04T04:55:49+00:00 hourly 0.9 https://trial.medpath.com/news/island-pharmaceuticals-raises-6-22-million-to-advance-dengue-fever-treatment-and-antiviral-pipeline 2025-07-04T04:54:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/island-pharmaceuticals-raises-6-22-million-to-advance-dengue-fever-treatment-and-antiviral-pipeline 2025-07-04T04:54:17+00:00 hourly 0.9 https://trial.medpath.com/news/neurizon-secures-global-license-with-elanco-for-als-drug-nuz-001-accelerating-path-to-market 2025-07-04T04:52:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurizon-secures-global-license-with-elanco-for-als-drug-nuz-001-accelerating-path-to-market 2025-07-04T04:52:30+00:00 hourly 0.9 https://trial.medpath.com/news/aquestive-therapeutics-receives-fda-approval-for-anaphylm-new-drug-application-targeting-2-billion-severe-allergic-reaction-market 2025-07-04T04:52:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aquestive-therapeutics-receives-fda-approval-for-anaphylm-new-drug-application-targeting-2-billion-severe-allergic-reaction-market 2025-07-04T04:52:21+00:00 hourly 0.9 https://trial.medpath.com/news/integra-lifesciences-launches-pediatric-registry-for-aera-eustachian-tube-balloon-dilation-system 2025-07-04T04:51:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integra-lifesciences-launches-pediatric-registry-for-aera-eustachian-tube-balloon-dilation-system 2025-07-04T04:51:37+00:00 hourly 0.9 https://trial.medpath.com/news/auriga-research-partners-with-san-francisco-research-institute-to-advance-ai-driven-clinical-research-across-global-markets 2025-07-04T04:51:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/auriga-research-partners-with-san-francisco-research-institute-to-advance-ai-driven-clinical-research-across-global-markets 2025-07-04T04:51:24+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-ctx310-shows-promising-lipid-reduction-results-in-phase-1-trial 2025-07-04T04:50:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-ctx310-shows-promising-lipid-reduction-results-in-phase-1-trial 2025-07-04T04:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-cosentyx-fails-to-meet-primary-endpoint-in-phase-iii-giant-cell-arteritis-trial 2025-07-04T04:46:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-cosentyx-fails-to-meet-primary-endpoint-in-phase-iii-giant-cell-arteritis-trial 2025-07-04T04:46:51+00:00 hourly 0.9 https://trial.medpath.com/news/hls-therapeutics-secures-nova-scotia-reimbursement-for-vascepa-expanding-cardiovascular-drug-access-to-95-of-eligible-canadians 2025-07-04T04:43:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hls-therapeutics-secures-nova-scotia-reimbursement-for-vascepa-expanding-cardiovascular-drug-access-to-95-of-eligible-canadians 2025-07-04T04:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/theratechnologies-agrees-to-254-million-private-acquisition-by-cb-biotechnology 2025-07-04T04:38:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theratechnologies-agrees-to-254-million-private-acquisition-by-cb-biotechnology 2025-07-04T04:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/jacobio-pharma-receives-ind-acceptance-for-bet-inhibitor-jab-8263-in-autoimmune-diseases 2025-07-04T04:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jacobio-pharma-receives-ind-acceptance-for-bet-inhibitor-jab-8263-in-autoimmune-diseases 2025-07-04T04:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-completes-phase-3b-asthma-study-evaluating-hfo-mdi-safety-and-launches-china-observational-study 2025-07-04T04:37:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-completes-phase-3b-asthma-study-evaluating-hfo-mdi-safety-and-launches-china-observational-study 2025-07-04T04:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/norwegian-researchers-report-promising-results-from-daratumumab-pilot-study-in-me-cfs-patients 2025-07-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norwegian-researchers-report-promising-results-from-daratumumab-pilot-study-in-me-cfs-patients 2025-07-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-raises-115-million-through-secondary-offering-to-fund-pipeline-development 2025-07-03T22:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nektar-therapeutics-raises-115-million-through-secondary-offering-to-fund-pipeline-development 2025-07-03T22:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/glucomodicum-s-needle-free-cgm-achieves-11-5-mard-in-646-patient-clinical-trial-nears-eu-regulatory-filing 2025-07-03T04:48:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glucomodicum-s-needle-free-cgm-achieves-11-5-mard-in-646-patient-clinical-trial-nears-eu-regulatory-filing 2025-07-03T04:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-blocks-mass-layoffs-at-hhs-citing-likely-unlawful-staff-cuts 2025-07-03T04:29:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-judge-blocks-mass-layoffs-at-hhs-citing-likely-unlawful-staff-cuts 2025-07-03T04:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-triple-combination-hypertension-pill-as-june-2025-delivers-major-cardiovascular-advances 2025-07-03T04:28:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-triple-combination-hypertension-pill-as-june-2025-delivers-major-cardiovascular-advances 2025-07-03T04:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-safety-alert-for-abiomed-blood-pump-controllers-following-three-patient-deaths 2025-07-03T01:16:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-safety-alert-for-abiomed-blood-pump-controllers-following-three-patient-deaths 2025-07-03T01:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-tiancimycin-based-antibody-drug-conjugate-shows-promise-against-aggressive-lymphoma 2025-07-03T01:16:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-tiancimycin-based-antibody-drug-conjugate-shows-promise-against-aggressive-lymphoma 2025-07-03T01:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-researchers-receive-3-5-million-nih-grant-to-develop-novel-mpox-antivirals-targeting-immune-evasion 2025-07-03T01:12:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-researchers-receive-3-5-million-nih-grant-to-develop-novel-mpox-antivirals-targeting-immune-evasion 2025-07-03T01:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-ai-powered-wristband-for-essential-tremor-treatment 2025-07-03T00:56:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-ai-powered-wristband-for-essential-tremor-treatment 2025-07-03T00:56:07+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-first-indigenous-dengue-vaccine-phase-3-trial-with-over-10000-participants 2025-07-03T00:44:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-first-indigenous-dengue-vaccine-phase-3-trial-with-over-10000-participants 2025-07-03T00:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-pharmaceutical-acquires-cantargia-s-can10-antibody-program-for-33-million-upfront-in-autoimmune-disease-deal 2025-07-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-pharmaceutical-acquires-cantargia-s-can10-antibody-program-for-33-million-upfront-in-autoimmune-disease-deal 2025-07-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/philips-receives-fda-clearance-for-ai-powered-mri-software-that-accelerates-scans-by-3x 2025-07-02T21:00:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philips-receives-fda-clearance-for-ai-powered-mri-software-that-accelerates-scans-by-3x 2025-07-02T21:00:33+00:00 hourly 0.9 https://trial.medpath.com/news/bxcl701-plus-pembrolizumab-shows-early-promise-in-second-line-pancreatic-cancer-treatment 2025-07-02T20:49:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bxcl701-plus-pembrolizumab-shows-early-promise-in-second-line-pancreatic-cancer-treatment 2025-07-02T20:49:12+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-gepotidacin-receives-fda-priority-review-for-gonorrhea-treatment 2025-07-02T20:49:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-gepotidacin-receives-fda-priority-review-for-gonorrhea-treatment 2025-07-02T20:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/novel-royalty-based-investment-fund-proposes-new-model-for-als-drug-development 2025-07-02T20:46:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-royalty-based-investment-fund-proposes-new-model-for-als-drug-development 2025-07-02T20:46:11+00:00 hourly 0.9 https://trial.medpath.com/news/regener-eyes-receives-fda-closure-of-voluntary-recall-returns-to-full-operations-with-enhanced-safety-features 2025-07-02T20:40:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regener-eyes-receives-fda-closure-of-voluntary-recall-returns-to-full-operations-with-enhanced-safety-features 2025-07-02T20:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-forms-spear-study-group-to-investigate-monoclonal-antibody-therapy-for-long-covid 2025-07-02T20:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-forms-spear-study-group-to-investigate-monoclonal-antibody-therapy-for-long-covid 2025-07-02T20:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/headlands-research-expands-to-caribbean-with-cmrcenter-acquisition-enhancing-hispanic-patient-access-to-clinical-trials 2025-07-02T20:25:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/headlands-research-expands-to-caribbean-with-cmrcenter-acquisition-enhancing-hispanic-patient-access-to-clinical-trials 2025-07-02T20:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/argon-ai-secures-5-5m-to-transform-pharmaceutical-data-management-with-ai-native-workspace 2025-07-02T20:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argon-ai-secures-5-5m-to-transform-pharmaceutical-data-management-with-ai-native-workspace 2025-07-02T20:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-orders-cdsco-to-review-safety-of-glp-1-diabetes-drugs-used-for-weight-loss 2025-07-02T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-orders-cdsco-to-review-safety-of-glp-1-diabetes-drugs-used-for-weight-loss 2025-07-02T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-and-shionogi-form-strategic-partnership-to-develop-novel-ntm-treatments-worth-up-to-chf-484-million 2025-07-02T17:28:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioversys-and-shionogi-form-strategic-partnership-to-develop-novel-ntm-treatments-worth-up-to-chf-484-million 2025-07-02T17:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/epo-and-upc-reach-opposite-conclusions-on-amgen-s-pcsk9-antibody-patent-validity 2025-07-02T17:25:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epo-and-upc-reach-opposite-conclusions-on-amgen-s-pcsk9-antibody-patent-validity 2025-07-02T17:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/ppp2r1a-mutations-predict-improved-survival-after-cancer-immunotherapy-in-ovarian-clear-cell-carcinoma 2025-07-02T17:22:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ppp2r1a-mutations-predict-improved-survival-after-cancer-immunotherapy-in-ovarian-clear-cell-carcinoma 2025-07-02T17:22:52+00:00 hourly 0.9 https://trial.medpath.com/news/fidelio-capital-acquires-majority-stake-in-alphalyse-to-expand-lc-ms-host-cell-protein-testing-globally 2025-07-02T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fidelio-capital-acquires-majority-stake-in-alphalyse-to-expand-lc-ms-host-cell-protein-testing-globally 2025-07-02T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/organon-discontinues-endometriosis-drug-og-6219-after-phase-ii-trial-failure 2025-07-02T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organon-discontinues-endometriosis-drug-og-6219-after-phase-ii-trial-failure 2025-07-02T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-s-bat4406f-achieves-early-trial-success-in-rare-neurological-disorder-nmosd 2025-07-02T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-thera-s-bat4406f-achieves-early-trial-success-in-rare-neurological-disorder-nmosd 2025-07-02T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/primo-biotechnology-raises-nt-220m-series-a-to-advance-radioligand-theranostics-platform 2025-07-02T17:12:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/primo-biotechnology-raises-nt-220m-series-a-to-advance-radioligand-theranostics-platform 2025-07-02T17:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/hemostemix-launches-commercial-sales-of-vescell-stem-cell-therapy-in-florida-under-new-legislation 2025-07-02T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemostemix-launches-commercial-sales-of-vescell-stem-cell-therapy-in-florida-under-new-legislation 2025-07-02T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-receives-fda-approval-for-tyzavantm-first-ready-to-infuse-vancomycin-formulation-for-sepsis-treatment 2025-07-02T17:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hikma-receives-fda-approval-for-tyzavantm-first-ready-to-infuse-vancomycin-formulation-for-sepsis-treatment 2025-07-02T17:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/kim-1-emerges-as-promising-prognostic-biomarker-in-advanced-renal-cell-carcinoma 2025-07-02T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kim-1-emerges-as-promising-prognostic-biomarker-in-advanced-renal-cell-carcinoma 2025-07-02T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/jcr-pharmaceuticals-completes-enrollment-in-global-phase-iii-trial-for-blood-brain-barrier-penetrating-hunter-syndrome-therapy 2025-07-02T17:03:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jcr-pharmaceuticals-completes-enrollment-in-global-phase-iii-trial-for-blood-brain-barrier-penetrating-hunter-syndrome-therapy 2025-07-02T17:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-completes-enrollment-in-phase-3-phoenix-trial-for-geographic-atrophy-treatment 2025-07-02T16:57:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-completes-enrollment-in-phase-3-phoenix-trial-for-geographic-atrophy-treatment 2025-07-02T16:57:24+00:00 hourly 0.9 https://trial.medpath.com/news/capsule-sponge-test-shows-promise-as-alternative-to-endoscopy-for-barrett-s-esophagus-monitoring 2025-07-02T16:53:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capsule-sponge-test-shows-promise-as-alternative-to-endoscopy-for-barrett-s-esophagus-monitoring 2025-07-02T16:53:42+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-reverses-patent-board-ruling-on-eye-redness-treatment-strengthens-brimonidine-patent-protection 2025-07-02T14:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-reverses-patent-board-ruling-on-eye-redness-treatment-strengthens-brimonidine-patent-protection 2025-07-02T14:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/rbc-capital-raises-xenon-pharmaceuticals-price-target-to-57-based-on-phase-iii-epilepsy-drug-optimism 2025-07-02T13:52:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rbc-capital-raises-xenon-pharmaceuticals-price-target-to-57-based-on-phase-iii-epilepsy-drug-optimism 2025-07-02T13:52:25+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-integrates-clonoseq-mrd-testing-into-flatiron-health-s-oncoemr-platform 2025-07-02T13:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptive-biotechnologies-integrates-clonoseq-mrd-testing-into-flatiron-health-s-oncoemr-platform 2025-07-02T13:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/australia-opens-first-antibody-drug-conjugate-manufacturing-facility-to-advance-precision-cancer-treatment 2025-07-02T08:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-opens-first-antibody-drug-conjugate-manufacturing-facility-to-advance-precision-cancer-treatment 2025-07-02T08:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/china-launches-commercial-insurance-catalog-to-accelerate-innovative-drug-development 2025-07-02T04:38:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-launches-commercial-insurance-catalog-to-accelerate-innovative-drug-development 2025-07-02T04:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-races-to-launch-first-generic-semaglutide-in-canada-as-wegovy-patents-expire 2025-07-02T04:38:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-races-to-launch-first-generic-semaglutide-in-canada-as-wegovy-patents-expire 2025-07-02T04:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-advances-cah-treatment-portfolio-with-long-acting-injectable-therapy 2025-07-02T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-advances-cah-treatment-portfolio-with-long-acting-injectable-therapy 2025-07-02T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-engineers-develop-first-immunocompetent-leukemia-on-a-chip-device-to-advance-car-t-cell-therapy-testing 2025-07-02T03:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyu-engineers-develop-first-immunocompetent-leukemia-on-a-chip-device-to-advance-car-t-cell-therapy-testing 2025-07-02T03:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/catalio-capital-closes-400m-fund-iv-to-back-healthcare-and-biotech-companies-amid-market-downturn 2025-07-02T02:13:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalio-capital-closes-400m-fund-iv-to-back-healthcare-and-biotech-companies-amid-market-downturn 2025-07-02T02:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-ceo-reportedly-considers-us-stock-listing-move-amid-uk-regulatory-frustrations 2025-07-02T02:11:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-ceo-reportedly-considers-us-stock-listing-move-amid-uk-regulatory-frustrations 2025-07-02T02:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/outlook-therapeutics-approaches-critical-fda-decision-for-lytenava-as-european-launch-validates-market-potential 2025-07-02T01:12:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outlook-therapeutics-approaches-critical-fda-decision-for-lytenava-as-european-launch-validates-market-potential 2025-07-02T01:12:45+00:00 hourly 0.9 https://trial.medpath.com/news/simtra-biopharma-solutions-completes-major-facility-expansion-in-germany-to-meet-growing-injectable-therapeutics-demand 2025-07-02T01:12:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simtra-biopharma-solutions-completes-major-facility-expansion-in-germany-to-meet-growing-injectable-therapeutics-demand 2025-07-02T01:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/first-oral-drug-ma-5-shows-promise-for-rare-barth-syndrome-in-preclinical-studies 2025-07-02T01:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-oral-drug-ma-5-shows-promise-for-rare-barth-syndrome-in-preclinical-studies 2025-07-02T01:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-secures-5-million-private-placement-to-advance-cancer-therapy-development 2025-07-02T00:16:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixte-biotechnology-secures-5-million-private-placement-to-advance-cancer-therapy-development 2025-07-02T00:16:05+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-secures-5m-funding-for-cancer-therapy-development-stock-surges-55 2025-07-02T00:16:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixte-biotechnology-secures-5m-funding-for-cancer-therapy-development-stock-surges-55 2025-07-02T00:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/house-republicans-subpoena-former-pfizer-executive-over-alleged-covid-19-vaccine-trial-delays 2025-07-02T00:14:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/house-republicans-subpoena-former-pfizer-executive-over-alleged-covid-19-vaccine-trial-delays 2025-07-02T00:14:29+00:00 hourly 0.9 https://trial.medpath.com/news/onward-medical-submits-fda-510-k-application-for-home-use-of-arc-ex-spinal-cord-stimulation-system 2025-07-02T00:12:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onward-medical-submits-fda-510-k-application-for-home-use-of-arc-ex-spinal-cord-stimulation-system 2025-07-02T00:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/oruka-therapeutics-promotes-laura-sandler-to-coo-as-company-advances-novel-psoriasis-pipeline 2025-07-01T23:14:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oruka-therapeutics-promotes-laura-sandler-to-coo-as-company-advances-novel-psoriasis-pipeline 2025-07-01T23:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/quiver-bioscience-secures-2-15m-nih-grant-to-develop-ai-powered-cns-drug-safety-platform 2025-07-01T23:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quiver-bioscience-secures-2-15m-nih-grant-to-develop-ai-powered-cns-drug-safety-platform 2025-07-01T23:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-advances-gene-therapy-pipeline-with-fda-rmat-designation-and-pivotal-trial-progress 2025-07-01T23:13:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meiragtx-advances-gene-therapy-pipeline-with-fda-rmat-designation-and-pivotal-trial-progress 2025-07-01T23:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/inhalation-sciences-secures-recurring-orders-from-global-pharma-customer-strengthening-preclinical-research-platform 2025-07-01T22:17:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhalation-sciences-secures-recurring-orders-from-global-pharma-customer-strengthening-preclinical-research-platform 2025-07-01T22:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-mrna-vaccine-shows-promise-against-deadly-elephant-virus-in-first-real-world-test 2025-07-01T21:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-mrna-vaccine-shows-promise-against-deadly-elephant-virus-in-first-real-world-test 2025-07-01T21:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/carthera-s-sonocloud-system-receives-ema-orphan-medical-device-endorsement-for-brain-tumor-treatment 2025-07-01T20:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carthera-s-sonocloud-system-receives-ema-orphan-medical-device-endorsement-for-brain-tumor-treatment 2025-07-01T20:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/sartorius-completes-80-million-acquisition-of-mattek-to-advance-3d-cell-model-technology 2025-07-01T20:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sartorius-completes-80-million-acquisition-of-mattek-to-advance-3d-cell-model-technology 2025-07-01T20:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/hanchorbio-secures-202m-licensing-deal-with-henlius-for-novel-cd47-targeting-cancer-immunotherapy 2025-07-01T20:30:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanchorbio-secures-202m-licensing-deal-with-henlius-for-novel-cd47-targeting-cancer-immunotherapy 2025-07-01T20:30:08+00:00 hourly 0.9 https://trial.medpath.com/news/rush-university-medical-center-launches-first-ever-apple-vision-pro-colonoscopy-study-with-ai-integration 2025-07-01T20:29:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rush-university-medical-center-launches-first-ever-apple-vision-pro-colonoscopy-study-with-ai-integration 2025-07-01T20:29:07+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-launches-precision-medicine-phase-2-trial-combining-opaganib-with-darolutamide-for-advanced-prostate-cancer 2025-07-01T20:29:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-biopharma-launches-precision-medicine-phase-2-trial-combining-opaganib-with-darolutamide-for-advanced-prostate-cancer 2025-07-01T20:29:05+00:00 hourly 0.9 https://trial.medpath.com/news/feliqs-secures-9-million-series-a-to-advance-novel-rop-prevention-therapy-flq-101 2025-07-01T20:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/feliqs-secures-9-million-series-a-to-advance-novel-rop-prevention-therapy-flq-101 2025-07-01T20:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-advances-pembrolizumab-biosimilar-development-as-herceptin-copy-nears-european-launch 2025-07-01T19:40:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-advances-pembrolizumab-biosimilar-development-as-herceptin-copy-nears-european-launch 2025-07-01T19:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/bluebird-bio-strengthens-leadership-team-with-three-key-executive-appointments 2025-07-01T19:17:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluebird-bio-strengthens-leadership-team-with-three-key-executive-appointments 2025-07-01T19:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/sonoclear-system-receives-fda-breakthrough-device-designation-for-enhanced-brain-tumor-surgery-imaging 2025-07-01T19:16:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonoclear-system-receives-fda-breakthrough-device-designation-for-enhanced-brain-tumor-surgery-imaging 2025-07-01T19:16:17+00:00 hourly 0.9 https://trial.medpath.com/news/senzime-secures-major-u-s-hospital-contract-and-new-patent-for-tetragraph-neuromuscular-monitoring-system 2025-07-01T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senzime-secures-major-u-s-hospital-contract-and-new-patent-for-tetragraph-neuromuscular-monitoring-system 2025-07-01T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-xdc-completes-singapore-manufacturing-facility-expanding-global-bioconjugate-production-network 2025-07-01T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-xdc-completes-singapore-manufacturing-facility-expanding-global-bioconjugate-production-network 2025-07-01T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/biovaxys-advances-dpx-platform-as-alternative-to-lipid-nanoparticles-for-mrna-vaccine-delivery 2025-07-01T17:21:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovaxys-advances-dpx-platform-as-alternative-to-lipid-nanoparticles-for-mrna-vaccine-delivery 2025-07-01T17:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/arctic-bioscience-s-hro350-shows-promise-in-phase-2b-psoriasis-trial-despite-missing-primary-endpoint 2025-07-01T17:19:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arctic-bioscience-s-hro350-shows-promise-in-phase-2b-psoriasis-trial-despite-missing-primary-endpoint 2025-07-01T17:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/inmagene-initiates-phase-2b-trial-of-img-007-anti-ox40-antibody-for-moderate-to-severe-atopic-dermatitis 2025-07-01T17:18:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmagene-initiates-phase-2b-trial-of-img-007-anti-ox40-antibody-for-moderate-to-severe-atopic-dermatitis 2025-07-01T17:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/adiposs-secures-chf-4-million-series-a-to-advance-brown-fat-imaging-technology-for-cancer-treatment-prediction 2025-07-01T17:17:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adiposs-secures-chf-4-million-series-a-to-advance-brown-fat-imaging-technology-for-cancer-treatment-prediction 2025-07-01T17:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/pixelgen-technologies-secures-14-7m-eic-funding-to-advance-single-cell-protein-interactome-analysis-platform 2025-07-01T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pixelgen-technologies-secures-14-7m-eic-funding-to-advance-single-cell-protein-interactome-analysis-platform 2025-07-01T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/news/ns-pharma-and-boston-children-s-hospital-form-strategic-alliance-to-advance-rare-disease-therapies 2025-07-01T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ns-pharma-and-boston-children-s-hospital-form-strategic-alliance-to-advance-rare-disease-therapies 2025-07-01T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-terminates-phase-ii-cd47-trial-in-blood-cancer-due-to-recruitment-challenges 2025-07-01T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-terminates-phase-ii-cd47-trial-in-blood-cancer-due-to-recruitment-challenges 2025-07-01T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-completes-manufacturing-transfer-of-synthetic-hypericin-for-rare-skin-cancer-treatment 2025-07-01T17:15:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soligenix-completes-manufacturing-transfer-of-synthetic-hypericin-for-rare-skin-cancer-treatment 2025-07-01T17:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/pharmnovo-advances-non-addictive-neuropathic-pain-drug-pn6047-with-phase-2-trial-application 2025-07-01T17:14:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmnovo-advances-non-addictive-neuropathic-pain-drug-pn6047-with-phase-2-trial-application 2025-07-01T17:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-invests-1-1-billion-in-european-biosimilar-manufacturing-hub-to-capture-222-billion-market-opportunity 2025-07-01T17:13:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-invests-1-1-billion-in-european-biosimilar-manufacturing-hub-to-capture-222-billion-market-opportunity 2025-07-01T17:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-partners-with-unnatural-products-in-1-5-billion-macrocyclic-peptide-deal 2025-07-01T16:25:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argenx-partners-with-unnatural-products-in-1-5-billion-macrocyclic-peptide-deal 2025-07-01T16:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/bio-usawa-and-bioeq-ag-partner-to-bring-ranibizumab-biosimilar-to-sub-saharan-africa 2025-07-01T16:23:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-usawa-and-bioeq-ag-partner-to-bring-ranibizumab-biosimilar-to-sub-saharan-africa 2025-07-01T16:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/arthrosi-therapeutics-achieves-rapid-enrollment-milestone-in-phase-3-gout-trial-for-pozdeutinurad 2025-07-01T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arthrosi-therapeutics-achieves-rapid-enrollment-milestone-in-phase-3-gout-trial-for-pozdeutinurad 2025-07-01T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/imagene-ai-secures-23m-series-b-led-by-larry-ellison-to-advance-multi-modal-foundation-models-for-precision-medicine 2025-07-01T16:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imagene-ai-secures-23m-series-b-led-by-larry-ellison-to-advance-multi-modal-foundation-models-for-precision-medicine 2025-07-01T16:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/oragenics-raises-20-million-to-advance-concussion-treatment-clinical-trials 2025-07-01T16:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oragenics-raises-20-million-to-advance-concussion-treatment-clinical-trials 2025-07-01T16:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/intrabio-completes-phase-iii-recruitment-for-ataxia-telangiectasia-treatment-in-record-time 2025-07-01T16:20:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intrabio-completes-phase-iii-recruitment-for-ataxia-telangiectasia-treatment-in-record-time 2025-07-01T16:20:34+00:00 hourly 0.9 https://trial.medpath.com/news/imunon-secures-nasdaq-listing-extension-to-advance-phase-3-ovarian-cancer-immunotherapy 2025-07-01T16:20:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imunon-secures-nasdaq-listing-extension-to-advance-phase-3-ovarian-cancer-immunotherapy 2025-07-01T16:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/oncternal-therapeutics-sells-ror1-targeting-programs-to-ho-ola-therapeutics-for-68-million-deal 2025-07-01T12:56:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncternal-therapeutics-sells-ror1-targeting-programs-to-ho-ola-therapeutics-for-68-million-deal 2025-07-01T12:56:40+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-pharmaceuticals-launches-global-phase-3-trial-for-ycanth-in-common-warts-targeting-22-million-us-patients 2025-07-01T12:56:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verrica-pharmaceuticals-launches-global-phase-3-trial-for-ycanth-in-common-warts-targeting-22-million-us-patients 2025-07-01T12:56:17+00:00 hourly 0.9 https://trial.medpath.com/news/ribociclib-kisqali-added-to-pbs-for-early-stage-breast-cancer-patients-in-australia 2025-07-01T12:55:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ribociclib-kisqali-added-to-pbs-for-early-stage-breast-cancer-patients-in-australia 2025-07-01T12:55:35+00:00 hourly 0.9 https://trial.medpath.com/news/lutroo-imaging-initiates-first-in-human-trial-of-radiocainetm-pet-tracer-for-pain-visualization 2025-07-01T12:54:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lutroo-imaging-initiates-first-in-human-trial-of-radiocainetm-pet-tracer-for-pain-visualization 2025-07-01T12:54:43+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-therapeutics-licenses-abeona-s-aav204-gene-therapy-platform-for-retinal-disease-treatment 2025-07-01T12:54:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beacon-therapeutics-licenses-abeona-s-aav204-gene-therapy-platform-for-retinal-disease-treatment 2025-07-01T12:54:36+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-secures-50-million-private-placement-to-advance-psychedelic-mental-health-therapies 2025-07-01T12:53:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atai-life-sciences-secures-50-million-private-placement-to-advance-psychedelic-mental-health-therapies 2025-07-01T12:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/apellis-secures-300-million-in-non-dilutive-financing-through-sobi-royalty-agreement-for-rare-kidney-disease-therapy 2025-07-01T12:53:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apellis-secures-300-million-in-non-dilutive-financing-through-sobi-royalty-agreement-for-rare-kidney-disease-therapy 2025-07-01T12:53:09+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-pharmaceutical-secures-nmpa-approval-for-jak1-inhibitor-ivarmacitinib-in-severe-alopecia-areata 2025-07-01T12:13:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-pharmaceutical-secures-nmpa-approval-for-jak1-inhibitor-ivarmacitinib-in-severe-alopecia-areata 2025-07-01T12:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/empnia-receives-fda-clearance-for-emotus-respiratory-motion-management-system-in-radiation-therapy 2025-07-01T12:13:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/empnia-receives-fda-clearance-for-emotus-respiratory-motion-management-system-in-radiation-therapy 2025-07-01T12:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-reports-3-year-survival-in-glioblastoma-patients-with-temferon-cell-therapy 2025-07-01T12:12:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genenta-reports-3-year-survival-in-glioblastoma-patients-with-temferon-cell-therapy 2025-07-01T12:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/sigvotatug-vedotin-shows-promise-in-nsclc-as-novel-integrin-beta-6-targeted-adc-advances-to-phase-3 2025-07-01T12:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sigvotatug-vedotin-shows-promise-in-nsclc-as-novel-integrin-beta-6-targeted-adc-advances-to-phase-3 2025-07-01T12:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-strengthens-leadership-team-with-appointment-of-chief-medical-officer-and-business-development-advisor 2025-07-01T09:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-strengthens-leadership-team-with-appointment-of-chief-medical-officer-and-business-development-advisor 2025-07-01T09:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/healx-partners-with-sci-ventures-in-2m-ai-driven-initiative-to-develop-spinal-cord-injury-treatments 2025-07-01T09:09:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healx-partners-with-sci-ventures-in-2m-ai-driven-initiative-to-develop-spinal-cord-injury-treatments 2025-07-01T09:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/drc-medicine-announces-422-million-spac-merger-to-advance-therapeutic-mask-technology-and-parkinson-s-drug-pipeline 2025-07-01T08:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drc-medicine-announces-422-million-spac-merger-to-advance-therapeutic-mask-technology-and-parkinson-s-drug-pipeline 2025-07-01T08:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/capsule-sponge-test-combined-with-biomarkers-shows-promise-for-barrett-esophagus-risk-stratification 2025-07-01T04:53:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capsule-sponge-test-combined-with-biomarkers-shows-promise-for-barrett-esophagus-risk-stratification 2025-07-01T04:53:29+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-raises-650-million-through-convertible-notes-to-advance-ai-driven-precision-medicine-platform 2025-07-01T04:13:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-raises-650-million-through-convertible-notes-to-advance-ai-driven-precision-medicine-platform 2025-07-01T04:13:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-iks014-her2-targeted-adc-enabling-us-clinical-trial-expansion 2025-07-01T04:13:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-iks014-her2-targeted-adc-enabling-us-clinical-trial-expansion 2025-07-01T04:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/third-line-mcrc-treatment-landscape-evolves-with-multiple-sequential-options-offering-modest-survival-benefits 2025-07-01T02:54:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/third-line-mcrc-treatment-landscape-evolves-with-multiple-sequential-options-offering-modest-survival-benefits 2025-07-01T02:54:08+00:00 hourly 0.9 https://trial.medpath.com/news/ambroxol-shows-promise-in-slowing-parkinson-s-disease-dementia-in-phase-ii-clinical-trial 2025-07-01T02:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ambroxol-shows-promise-in-slowing-parkinson-s-disease-dementia-in-phase-ii-clinical-trial 2025-07-01T02:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-initiates-phase-1-trial-for-long-acting-cah-treatment-nbip-01435 2025-07-01T00:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-initiates-phase-1-trial-for-long-acting-cah-treatment-nbip-01435 2025-07-01T00:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/chemoimmunotherapy-shows-limited-efficacy-in-younger-patients-with-extensive-stage-small-cell-lung-cancer 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemoimmunotherapy-shows-limited-efficacy-in-younger-patients-with-extensive-stage-small-cell-lung-cancer 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-face-massive-revenue-losses-as-patent-cliff-hits-key-blockbusters 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-companies-face-massive-revenue-losses-as-patent-cliff-hits-key-blockbusters 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/radiotherapy-immunotherapy-combinations-show-promise-for-enhanced-cancer-treatment-through-abscopal-effects 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiotherapy-immunotherapy-combinations-show-promise-for-enhanced-cancer-treatment-through-abscopal-effects 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ich-releases-draft-e20-guideline-on-adaptive-clinical-trial-designs-for-global-harmonization 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ich-releases-draft-e20-guideline-on-adaptive-clinical-trial-designs-for-global-harmonization 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/somai-pharmaceuticals-acquires-rpk-biopharma-strengthening-global-cannabis-manufacturing-leadership 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/somai-pharmaceuticals-acquires-rpk-biopharma-strengthening-global-cannabis-manufacturing-leadership 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-analysis-reveals-new-cardiovascular-risks-for-hyperkalemia-drug-sodium-zirconium-cyclosilicate 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-safety-analysis-reveals-new-cardiovascular-risks-for-hyperkalemia-drug-sodium-zirconium-cyclosilicate 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-launches-phase-1b-2-trial-of-dual-car-t-therapy-azd0120-for-refractory-systemic-lupus-erythematosus 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-launches-phase-1b-2-trial-of-dual-car-t-therapy-azd0120-for-refractory-systemic-lupus-erythematosus 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-therapeutics-advances-pn-477-triple-agonist-for-obesity-treatment-targeting-same-mechanism-as-eli-lilly-s-retatrutide 2025-06-30T23:12:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-therapeutics-advances-pn-477-triple-agonist-for-obesity-treatment-targeting-same-mechanism-as-eli-lilly-s-retatrutide 2025-06-30T23:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-stock-surges-over-130-following-positive-preclinical-depression-data-and-first-in-human-pain-trial-results 2025-06-30T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artelo-biosciences-stock-surges-over-130-following-positive-preclinical-depression-data-and-first-in-human-pain-trial-results 2025-06-30T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-new-safety-warnings-for-adhd-stimulants-in-children-under-six 2025-06-30T21:11:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-mandates-new-safety-warnings-for-adhd-stimulants-in-children-under-six 2025-06-30T21:11:59+00:00 hourly 0.9 https://trial.medpath.com/news/partial-breast-radiation-proves-non-inferior-to-whole-breast-treatment-in-10-year-follow-up-of-uk-import-low-trial 2025-06-30T20:17:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/partial-breast-radiation-proves-non-inferior-to-whole-breast-treatment-in-10-year-follow-up-of-uk-import-low-trial 2025-06-30T20:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-health-enrolls-first-patient-in-novel-carotid-stent-trial-targeting-stroke-prevention 2025-06-30T20:16:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-health-enrolls-first-patient-in-novel-carotid-stent-trial-targeting-stroke-prevention 2025-06-30T20:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bispecific-antibody-shows-promise-for-autoimmune-disease-treatment-in-preclinical-studies 2025-06-30T19:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bispecific-antibody-shows-promise-for-autoimmune-disease-treatment-in-preclinical-studies 2025-06-30T19:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-screen-reveals-key-to-enhancing-rna-drug-efficacy-through-endosomal-transport-modulation 2025-06-30T19:13:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-screen-reveals-key-to-enhancing-rna-drug-efficacy-through-endosomal-transport-modulation 2025-06-30T19:13:57+00:00 hourly 0.9 https://trial.medpath.com/news/zilucoplan-shows-sustained-efficacy-and-steroid-sparing-benefits-in-long-term-myasthenia-gravis-treatment 2025-06-30T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zilucoplan-shows-sustained-efficacy-and-steroid-sparing-benefits-in-long-term-myasthenia-gravis-treatment 2025-06-30T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/applied-dna-sciences-restructures-operations-to-focus-on-synthetic-dna-manufacturing-for-gene-therapies 2025-06-30T18:16:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-dna-sciences-restructures-operations-to-focus-on-synthetic-dna-manufacturing-for-gene-therapies 2025-06-30T18:16:20+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-acquires-full-us-rights-to-ameluz-and-rhodoled-secures-11m-funding 2025-06-30T16:45:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-acquires-full-us-rights-to-ameluz-and-rhodoled-secures-11m-funding 2025-06-30T16:45:50+00:00 hourly 0.9 https://trial.medpath.com/news/cd19-car-t-cell-therapy-shows-promise-in-relapsed-t-8-21-aml-despite-short-term-remission 2025-06-30T16:43:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd19-car-t-cell-therapy-shows-promise-in-relapsed-t-8-21-aml-despite-short-term-remission 2025-06-30T16:43:27+00:00 hourly 0.9 https://trial.medpath.com/news/avencell-secures-40-million-amed-grant-to-advance-dual-antigen-allogeneic-car-t-therapy-for-b-cell-lymphomas 2025-06-30T16:43:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avencell-secures-40-million-amed-grant-to-advance-dual-antigen-allogeneic-car-t-therapy-for-b-cell-lymphomas 2025-06-30T16:43:19+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-acquires-capstan-therapeutics-for-2-1-billion-to-advance-in-vivo-car-t-technology-for-autoimmune-diseases 2025-06-30T16:43:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-acquires-capstan-therapeutics-for-2-1-billion-to-advance-in-vivo-car-t-technology-for-autoimmune-diseases 2025-06-30T16:43:14+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-plus-bevacizumab-emerges-as-optimal-first-line-treatment-for-advanced-hepatocellular-carcinoma 2025-06-30T16:43:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atezolizumab-plus-bevacizumab-emerges-as-optimal-first-line-treatment-for-advanced-hepatocellular-carcinoma 2025-06-30T16:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/assembly-biosciences-initiates-phase-1b-trial-of-long-acting-hsv-helicase-primase-inhibitor-abi-1179 2025-06-30T16:39:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/assembly-biosciences-initiates-phase-1b-trial-of-long-acting-hsv-helicase-primase-inhibitor-abi-1179 2025-06-30T16:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/logicflo-ai-secures-2-7m-to-deploy-ai-agents-across-life-sciences-operations 2025-06-30T16:36:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/logicflo-ai-secures-2-7m-to-deploy-ai-agents-across-life-sciences-operations 2025-06-30T16:36:07+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-acquires-in-vivo-car-t-developer-capstan-therapeutics-for-up-to-2-1-billion 2025-06-30T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-acquires-in-vivo-car-t-developer-capstan-therapeutics-for-up-to-2-1-billion 2025-06-30T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-reveals-mixed-benefits-of-first-line-vs-second-line-cdk4-6-inhibitor-therapy-in-hr-her2-metastatic-breast-cancer 2025-06-30T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-reveals-mixed-benefits-of-first-line-vs-second-line-cdk4-6-inhibitor-therapy-in-hr-her2-metastatic-breast-cancer 2025-06-30T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-s-bispecific-antibody-success-from-3m-startup-to-15b-global-biotech-leader 2025-06-30T16:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-s-bispecific-antibody-success-from-3m-startup-to-15b-global-biotech-leader 2025-06-30T16:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-fusion-and-curadh-form-strategic-partnership-to-advance-astatine-211-radiopharmaceuticals 2025-06-30T16:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-fusion-and-curadh-form-strategic-partnership-to-advance-astatine-211-radiopharmaceuticals 2025-06-30T16:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-and-summit-therapeutics-launch-clinical-collaboration-to-test-ras-inhibitor-combinations-with-bispecific-antibody 2025-06-30T16:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-and-summit-therapeutics-launch-clinical-collaboration-to-test-ras-inhibitor-combinations-with-bispecific-antibody 2025-06-30T16:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-toby-s-ai-powered-urine-test-for-bladder-cancer-detection 2025-06-30T16:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-toby-s-ai-powered-urine-test-for-bladder-cancer-detection 2025-06-30T16:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-ai-submits-de-novo-fda-application-for-ai-powered-burn-assessment-device 2025-06-30T16:30:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spectral-ai-submits-de-novo-fda-application-for-ai-powered-burn-assessment-device 2025-06-30T16:30:48+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-pmprb-releases-new-drug-price-review-guidelines-implementing-two-step-process-starting-january-2026 2025-06-30T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-s-pmprb-releases-new-drug-price-review-guidelines-implementing-two-step-process-starting-january-2026 2025-06-30T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/portal-biotech-secures-35m-series-a-to-commercialize-world-s-first-full-length-single-molecule-protein-sequencer 2025-06-30T16:30:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/portal-biotech-secures-35m-series-a-to-commercialize-world-s-first-full-length-single-molecule-protein-sequencer 2025-06-30T16:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-takeda-s-gammagard-liquid-erc-first-ready-to-use-low-iga-immunoglobulin-therapy-for-primary-immunodeficiency 2025-06-30T16:18:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-takeda-s-gammagard-liquid-erc-first-ready-to-use-low-iga-immunoglobulin-therapy-for-primary-immunodeficiency 2025-06-30T16:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-review-of-skinvive-by-juvederm-for-neck-line-treatment-expansion 2025-06-30T16:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-review-of-skinvive-by-juvederm-for-neck-line-treatment-expansion 2025-06-30T16:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-bemarituzumab-shows-significant-survival-benefit-in-phase-3-gastric-cancer-trial 2025-06-30T16:18:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-bemarituzumab-shows-significant-survival-benefit-in-phase-3-gastric-cancer-trial 2025-06-30T16:18:45+00:00 hourly 0.9 https://trial.medpath.com/news/dual-ctla-4-and-pd-1-blockade-shows-superior-efficacy-in-melanoma-brain-metastases 2025-06-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-ctla-4-and-pd-1-blockade-shows-superior-efficacy-in-melanoma-brain-metastases 2025-06-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pembrolizumab-vorinostat-combination-shows-promise-in-recurrent-squamous-cell-carcinoma 2025-06-30T12:58:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pembrolizumab-vorinostat-combination-shows-promise-in-recurrent-squamous-cell-carcinoma 2025-06-30T12:58:55+00:00 hourly 0.9 https://trial.medpath.com/news/laverock-therapeutics-raises-ps20m-in-expanded-seed-funding-reports-positive-data-for-cancer-cell-therapy-programs 2025-06-30T12:58:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laverock-therapeutics-raises-ps20m-in-expanded-seed-funding-reports-positive-data-for-cancer-cell-therapy-programs 2025-06-30T12:58:38+00:00 hourly 0.9 https://trial.medpath.com/news/vetter-breaks-ground-on-285-million-clinical-manufacturing-facility-in-illinois 2025-06-30T12:57:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vetter-breaks-ground-on-285-million-clinical-manufacturing-facility-in-illinois 2025-06-30T12:57:02+00:00 hourly 0.9 https://trial.medpath.com/news/epigenica-secures-2-2m-to-advance-high-throughput-epigenetic-screening-platform 2025-06-30T12:18:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epigenica-secures-2-2m-to-advance-high-throughput-epigenetic-screening-platform 2025-06-30T12:18:33+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-orpathys-tagrisso-combination-for-egfr-mutated-lung-cancer-with-met-amplification 2025-06-30T12:16:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-orpathys-tagrisso-combination-for-egfr-mutated-lung-cancer-with-met-amplification 2025-06-30T12:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-appoints-christine-coyne-as-chief-commercial-officer-to-lead-orlynvah-launch 2025-06-30T12:14:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterum-therapeutics-appoints-christine-coyne-as-chief-commercial-officer-to-lead-orlynvah-launch 2025-06-30T12:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-secures-300-million-royalty-financing-to-support-attr-cm-drug-launch 2025-06-30T12:14:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-secures-300-million-royalty-financing-to-support-attr-cm-drug-launch 2025-06-30T12:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-launches-wuxihigh22-0-platform-achieving-record-230-mg-ml-protein-concentrations 2025-06-30T12:14:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-launches-wuxihigh22-0-platform-achieving-record-230-mg-ml-protein-concentrations 2025-06-30T12:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/celcuity-s-gedatolisib-shows-promising-results-in-prostate-and-breast-cancer-trials 2025-06-30T12:14:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celcuity-s-gedatolisib-shows-promising-results-in-prostate-and-breast-cancer-trials 2025-06-30T12:14:23+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-completes-200-patient-study-revealing-40-mortality-rate-in-acute-melioidosis 2025-06-30T12:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an2-therapeutics-completes-200-patient-study-revealing-40-mortality-rate-in-acute-melioidosis 2025-06-30T12:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/marksans-pharma-subsidiary-receives-fda-establishment-inspection-report-following-new-york-facility-review 2025-06-30T08:58:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marksans-pharma-subsidiary-receives-fda-establishment-inspection-report-following-new-york-facility-review 2025-06-30T08:58:01+00:00 hourly 0.9 https://trial.medpath.com/news/neurizon-therapeutics-develops-oral-liquid-formulation-of-nuz-001-for-als-patients-with-swallowing-difficulties 2025-06-30T08:57:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurizon-therapeutics-develops-oral-liquid-formulation-of-nuz-001-for-als-patients-with-swallowing-difficulties 2025-06-30T08:57:53+00:00 hourly 0.9 https://trial.medpath.com/news/faron-research-reveals-novel-immune-evasion-mechanism-validates-bexmarilimab-s-therapeutic-approach 2025-06-30T08:57:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-research-reveals-novel-immune-evasion-mechanism-validates-bexmarilimab-s-therapeutic-approach 2025-06-30T08:57:51+00:00 hourly 0.9 https://trial.medpath.com/news/esteve-acquires-caprelsa-rights-from-sanofi-to-expand-rare-cancer-treatment-portfolio 2025-06-30T08:54:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esteve-acquires-caprelsa-rights-from-sanofi-to-expand-rare-cancer-treatment-portfolio 2025-06-30T08:54:15+00:00 hourly 0.9 https://trial.medpath.com/news/roche-announces-leadership-changes-as-head-of-pharma-r-d-hans-clevers-retires 2025-06-30T08:53:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-announces-leadership-changes-as-head-of-pharma-r-d-hans-clevers-retires 2025-06-30T08:53:30+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-advances-argx-119-to-registrational-study-for-ultra-rare-congenital-myasthenic-syndromes 2025-06-30T08:51:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argenx-advances-argx-119-to-registrational-study-for-ultra-rare-congenital-myasthenic-syndromes 2025-06-30T08:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/stalicla-secures-chf-2-million-financing-from-addex-therapeutics-to-advance-precision-medicine-for-autism-and-neurodevelopmental-disorders 2025-06-30T08:51:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stalicla-secures-chf-2-million-financing-from-addex-therapeutics-to-advance-precision-medicine-for-autism-and-neurodevelopmental-disorders 2025-06-30T08:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/klotho-neurosciences-advances-gene-therapy-manufacturing-for-als-treatment 2025-06-30T08:50:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/klotho-neurosciences-advances-gene-therapy-manufacturing-for-als-treatment 2025-06-30T08:50:45+00:00 hourly 0.9 https://trial.medpath.com/news/investor-challenges-avadel-board-over-alleged-lumryz-launch-mismanagement 2025-06-30T04:52:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/investor-challenges-avadel-board-over-alleged-lumryz-launch-mismanagement 2025-06-30T04:52:09+00:00 hourly 0.9 https://trial.medpath.com/news/ltr-pharma-s-intranasal-erectile-dysfunction-treatment-spontan-demonstrates-470-faster-absorption-in-pivotal-study 2025-06-30T04:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ltr-pharma-s-intranasal-erectile-dysfunction-treatment-spontan-demonstrates-470-faster-absorption-in-pivotal-study 2025-06-30T04:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-reports-mixed-phase-2b-results-as-bpl-003-succeeds-while-inidascamine-falls-short 2025-06-30T04:51:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atai-life-sciences-reports-mixed-phase-2b-results-as-bpl-003-succeeds-while-inidascamine-falls-short 2025-06-30T04:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-rmit-developed-ingestible-gas-capsule-for-diagnosing-gut-motility-disorders 2025-06-30T04:12:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-rmit-developed-ingestible-gas-capsule-for-diagnosing-gut-motility-disorders 2025-06-30T04:12:34+00:00 hourly 0.9 https://trial.medpath.com/news/aurinia-s-aritinercept-shows-promising-safety-and-efficacy-in-phase-1-trial-for-autoimmune-diseases 2025-06-30T04:12:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurinia-s-aritinercept-shows-promising-safety-and-efficacy-in-phase-1-trial-for-autoimmune-diseases 2025-06-30T04:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/spatial-molecular-imaging-reveals-critical-immune-response-patterns-in-pig-to-human-kidney-xenotransplantation 2025-06-30T00:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spatial-molecular-imaging-reveals-critical-immune-response-patterns-in-pig-to-human-kidney-xenotransplantation 2025-06-30T00:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/remdesivir-shows-modest-reduction-in-long-covid-risk-among-hospitalized-patients 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remdesivir-shows-modest-reduction-in-long-covid-risk-among-hospitalized-patients 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adhd-medication-benefits-diminish-as-prescription-rates-rise-swedish-study-reveals 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adhd-medication-benefits-diminish-as-prescription-rates-rise-swedish-study-reveals 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/seven-year-us-safety-data-confirms-brodalumab-s-stable-risk-profile-in-psoriasis-treatment 2025-06-29T20:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seven-year-us-safety-data-confirms-brodalumab-s-stable-risk-profile-in-psoriasis-treatment 2025-06-29T20:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/brain-imaging-reveals-why-parkinson-s-drug-levodopa-fails-some-patients 2025-06-29T19:12:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-imaging-reveals-why-parkinson-s-drug-levodopa-fails-some-patients 2025-06-29T19:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/metabolomics-study-identifies-angiotensin-iv-as-highly-accurate-biomarker-for-tuberculosis-diagnosis 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolomics-study-identifies-angiotensin-iv-as-highly-accurate-biomarker-for-tuberculosis-diagnosis 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-immunotherapy-advances-target-uveal-melanoma-s-resistance-mechanisms 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-immunotherapy-advances-target-uveal-melanoma-s-resistance-mechanisms 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-voranigo-vorasidenib-as-first-targeted-therapy-for-idh-mutant-glioma 2025-06-29T12:47:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-voranigo-vorasidenib-as-first-targeted-therapy-for-idh-mutant-glioma 2025-06-29T12:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/karnataka-government-seeks-dcgi-investigation-into-hcg-clinical-trial-ethics-violations 2025-06-29T05:10:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karnataka-government-seeks-dcgi-investigation-into-hcg-clinical-trial-ethics-violations 2025-06-29T05:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/trichoscopy-emerges-as-key-diagnostic-tool-for-early-detection-and-differentiation-of-alopecia-types 2025-06-29T02:52:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trichoscopy-emerges-as-key-diagnostic-tool-for-early-detection-and-differentiation-of-alopecia-types 2025-06-29T02:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-therapy-linked-to-8-9-fold-increased-risk-of-secondary-t-cell-lymphoma-in-global-study 2025-06-29T01:10:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-therapy-linked-to-8-9-fold-increased-risk-of-secondary-t-cell-lymphoma-in-global-study 2025-06-29T01:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/icon-group-invests-18-7-million-in-advanced-radiotherapy-technology-partnership-with-varian-to-address-uk-cancer-care-gap 2025-06-29T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icon-group-invests-18-7-million-in-advanced-radiotherapy-technology-partnership-with-varian-to-address-uk-cancer-care-gap 2025-06-29T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/cansino-biologics-launches-phase-3-covid-19-vaccine-trial-in-pakistan-despite-declining-case-numbers 2025-06-29T01:09:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cansino-biologics-launches-phase-3-covid-19-vaccine-trial-in-pakistan-despite-declining-case-numbers 2025-06-29T01:09:55+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-achieve-3d-printing-breakthrough-for-type-1-diabetes-treatment-using-functional-human-islets 2025-06-29T00:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-achieve-3d-printing-breakthrough-for-type-1-diabetes-treatment-using-functional-human-islets 2025-06-29T00:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/china-medical-system-files-for-secondary-sgx-listing-to-expand-southeast-asia-operations 2025-06-28T21:12:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-medical-system-files-for-secondary-sgx-listing-to-expand-southeast-asia-operations 2025-06-28T21:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-biopharma-secures-600-private-placement-to-advance-multiple-sclerosis-drug-development 2025-06-28T20:10:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-biopharma-secures-600-private-placement-to-advance-multiple-sclerosis-drug-development 2025-06-28T20:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-raises-19m-to-advance-alzheimer-s-neuroinflammation-therapy-ahead-of-pivotal-trial-results 2025-06-28T17:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-raises-19m-to-advance-alzheimer-s-neuroinflammation-therapy-ahead-of-pivotal-trial-results 2025-06-28T17:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-partners-with-pfizer-and-lumina-in-fibre-consortium-to-transform-fibrotic-disease-clinical-trials 2025-06-28T17:03:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantheus-partners-with-pfizer-and-lumina-in-fibre-consortium-to-transform-fibrotic-disease-clinical-trials 2025-06-28T17:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-rejects-johnson-johnson-s-340b-drug-pricing-rebate-model 2025-06-28T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-rejects-johnson-johnson-s-340b-drug-pricing-rebate-model 2025-06-28T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-drug-market-sees-780-investment-surge-following-leqembi-and-kisunla-approvals 2025-06-28T17:03:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-drug-market-sees-780-investment-surge-following-leqembi-and-kisunla-approvals 2025-06-28T17:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-pharmaceuticals-commits-1-billion-to-expand-us-generic-medicine-manufacturing-through-2030 2025-06-28T16:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hikma-pharmaceuticals-commits-1-billion-to-expand-us-generic-medicine-manufacturing-through-2030 2025-06-28T16:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/india-mandates-digital-only-applications-for-who-gmp-and-copp-certificates-through-ondls-portal 2025-06-28T13:11:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-mandates-digital-only-applications-for-who-gmp-and-copp-certificates-through-ondls-portal 2025-06-28T13:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/iridex-enrolls-first-patient-in-dame-trial-testing-micropulse-laser-as-adjunct-to-anti-vegf-therapy-for-severe-diabetic-macular-edema 2025-06-28T13:11:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iridex-enrolls-first-patient-in-dame-trial-testing-micropulse-laser-as-adjunct-to-anti-vegf-therapy-for-severe-diabetic-macular-edema 2025-06-28T13:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-recalls-over-4600-bottles-of-acetaminophen-in-us-due-to-tablet-discoloration 2025-06-28T13:11:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-pharma-recalls-over-4600-bottles-of-acetaminophen-in-us-due-to-tablet-discoloration 2025-06-28T13:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/cook-medical-issues-class-i-recall-of-beacon-tip-catheters-following-tip-separation-injuries 2025-06-28T11:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cook-medical-issues-class-i-recall-of-beacon-tip-catheters-following-tip-separation-injuries 2025-06-28T11:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/torrent-pharma-advances-2-4-billion-acquisition-of-jb-chemicals-in-major-industry-consolidation-move 2025-06-28T08:11:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/torrent-pharma-advances-2-4-billion-acquisition-of-jb-chemicals-in-major-industry-consolidation-move 2025-06-28T08:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/natural-polymers-emerge-as-promising-platform-for-advanced-insulin-delivery-systems 2025-06-28T08:10:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natural-polymers-emerge-as-promising-platform-for-advanced-insulin-delivery-systems 2025-06-28T08:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-corporation-to-acquire-turnstone-biologics-for-0-34-per-share-plus-contingent-value-rights 2025-06-28T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-royalty-corporation-to-acquire-turnstone-biologics-for-0-34-per-share-plus-contingent-value-rights 2025-06-28T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/urine-dna-test-predicts-bladder-cancer-recurrence-after-immunotherapy-treatment 2025-06-28T05:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urine-dna-test-predicts-bladder-cancer-recurrence-after-immunotherapy-treatment 2025-06-28T05:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/selinexor-maintenance-therapy-shows-sustained-benefit-in-tp53-wild-type-advanced-endometrial-cancer 2025-06-28T05:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selinexor-maintenance-therapy-shows-sustained-benefit-in-tp53-wild-type-advanced-endometrial-cancer 2025-06-28T05:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-for-daraxonrasib-in-kras-mutated-pancreatic-cancer 2025-06-28T04:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-for-daraxonrasib-in-kras-mutated-pancreatic-cancer 2025-06-28T04:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/paralyzed-veteran-becomes-first-neuralink-brain-computer-interface-recipient-at-university-of-miami 2025-06-28T04:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paralyzed-veteran-becomes-first-neuralink-brain-computer-interface-recipient-at-university-of-miami 2025-06-28T04:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-guidelines-update-treatment-sequencing-for-metastatic-gastrointestinal-stromal-tumors 2025-06-28T03:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccn-guidelines-update-treatment-sequencing-for-metastatic-gastrointestinal-stromal-tumors 2025-06-28T03:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/cellular-senescence-gene-signature-reveals-new-biomarkers-for-idiopathic-pulmonary-fibrosis 2025-06-28T03:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellular-senescence-gene-signature-reveals-new-biomarkers-for-idiopathic-pulmonary-fibrosis 2025-06-28T03:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/bcma-targeted-car-t-therapy-achieves-96-3-response-rate-in-relapsed-multiple-myeloma-study 2025-06-28T01:12:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bcma-targeted-car-t-therapy-achieves-96-3-response-rate-in-relapsed-multiple-myeloma-study 2025-06-28T01:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-gamifant-as-first-treatment-for-macrophage-activation-syndrome-in-still-s-disease 2025-06-28T00:11:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-gamifant-as-first-treatment-for-macrophage-activation-syndrome-in-still-s-disease 2025-06-28T00:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/cessatech-reports-75-pain-reduction-in-pediatric-acute-pain-study-eyes-us-launch-by-end-2025 2025-06-28T00:10:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cessatech-reports-75-pain-reduction-in-pediatric-acute-pain-study-eyes-us-launch-by-end-2025 2025-06-28T00:10:35+00:00 hourly 0.9 https://trial.medpath.com/news/retinalgenix-partners-with-labcorp-to-launch-dna-gps-platform-for-genetic-and-retinal-disease-screening 2025-06-27T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retinalgenix-partners-with-labcorp-to-launch-dna-gps-platform-for-genetic-and-retinal-disease-screening 2025-06-27T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/prd-therapeutics-initiates-first-in-human-trial-of-soat2-selective-inhibitor-prd001-for-rare-cholesterol-disorders 2025-06-27T21:12:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prd-therapeutics-initiates-first-in-human-trial-of-soat2-selective-inhibitor-prd001-for-rare-cholesterol-disorders 2025-06-27T21:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/bioporto-launches-pronephro-aki-diagnostic-test-in-us-market-through-roche-partnership 2025-06-27T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioporto-launches-pronephro-aki-diagnostic-test-in-us-market-through-roche-partnership 2025-06-27T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-tovorafenib-offers-new-treatment-option-for-pediatric-low-grade-glioma-with-braf-v600-mutations 2025-06-27T20:46:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-tovorafenib-offers-new-treatment-option-for-pediatric-low-grade-glioma-with-braf-v600-mutations 2025-06-27T20:46:59+00:00 hourly 0.9 https://trial.medpath.com/news/patient-derived-esophageal-cancer-organ-chips-accurately-predict-chemotherapy-response-in-clinical-study 2025-06-27T20:13:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-derived-esophageal-cancer-organ-chips-accurately-predict-chemotherapy-response-in-clinical-study 2025-06-27T20:13:01+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-normalizes-brain-blood-flow-in-sickle-cell-disease-patients-reducing-stroke-risk 2025-06-27T20:11:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-normalizes-brain-blood-flow-in-sickle-cell-disease-patients-reducing-stroke-risk 2025-06-27T20:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/novel-vms-therapy-shows-early-promise-in-improving-quality-of-life-for-breast-cancer-patients 2025-06-27T16:54:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-vms-therapy-shows-early-promise-in-improving-quality-of-life-for-breast-cancer-patients 2025-06-27T16:54:07+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-pharmaceuticals-divests-european-orladeyo-rights-for-264-million-to-achieve-debt-free-status 2025-06-27T16:53:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocryst-pharmaceuticals-divests-european-orladeyo-rights-for-264-million-to-achieve-debt-free-status 2025-06-27T16:53:15+00:00 hourly 0.9 https://trial.medpath.com/news/stentit-initiates-first-in-human-trial-of-regenerative-stent-for-chronic-limb-threatening-ischemia 2025-06-27T16:52:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stentit-initiates-first-in-human-trial-of-regenerative-stent-for-chronic-limb-threatening-ischemia 2025-06-27T16:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-navigates-eylea-decline-with-pipeline-diversification-and-regulatory-wins 2025-06-27T16:52:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-navigates-eylea-decline-with-pipeline-diversification-and-regulatory-wins 2025-06-27T16:52:12+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-achieves-100-survival-rate-with-novel-t-cell-engagers-in-pancreatic-cancer-preclinical-study 2025-06-27T16:13:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hcw-biologics-achieves-100-survival-rate-with-novel-t-cell-engagers-in-pancreatic-cancer-preclinical-study 2025-06-27T16:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-maintains-record-breaking-approval-pace-despite-organizational-upheaval-highlighting-three-breakthrough-therapies 2025-06-27T16:11:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-maintains-record-breaking-approval-pace-despite-organizational-upheaval-highlighting-three-breakthrough-therapies 2025-06-27T16:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/swissmedic-launches-fast-track-clinical-trial-review-to-accelerate-patient-access-to-life-saving-treatments 2025-06-27T16:11:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swissmedic-launches-fast-track-clinical-trial-review-to-accelerate-patient-access-to-life-saving-treatments 2025-06-27T16:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/transthera-s-tinengotinib-shows-promise-against-fgfr-resistant-cholangiocarcinoma-in-annals-of-oncology-study 2025-06-27T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transthera-s-tinengotinib-shows-promise-against-fgfr-resistant-cholangiocarcinoma-in-annals-of-oncology-study 2025-06-27T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-s-sgr-1505-receives-fda-fast-track-designation-for-relapsed-waldenstrom-macroglobulinemia 2025-06-27T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schrodinger-s-sgr-1505-receives-fda-fast-track-designation-for-relapsed-waldenstrom-macroglobulinemia 2025-06-27T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/bharat-biotech-and-gsk-pledge-to-cut-malaria-vaccine-price-by-more-than-half-to-under-5-by-2028 2025-06-27T15:11:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bharat-biotech-and-gsk-pledge-to-cut-malaria-vaccine-price-by-more-than-half-to-under-5-by-2028 2025-06-27T15:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/tc-biopharm-leads-gamma-delta-t-cell-therapy-development-with-over-25-clinical-programs-worldwide 2025-06-27T15:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tc-biopharm-leads-gamma-delta-t-cell-therapy-development-with-over-25-clinical-programs-worldwide 2025-06-27T15:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/complement-based-drug-development-gains-momentum-following-fda-approvals-and-pipeline-advances 2025-06-27T14:40:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/complement-based-drug-development-gains-momentum-following-fda-approvals-and-pipeline-advances 2025-06-27T14:40:59+00:00 hourly 0.9 https://trial.medpath.com/news/indian-crdmos-gain-momentum-as-global-pharma-diversifies-manufacturing-operations 2025-06-27T13:15:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-crdmos-gain-momentum-as-global-pharma-diversifies-manufacturing-operations 2025-06-27T13:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/bone-biologics-files-patent-application-for-novel-nell-1-protein-technology-in-spine-fusion 2025-06-27T13:15:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bone-biologics-files-patent-application-for-novel-nell-1-protein-technology-in-spine-fusion 2025-06-27T13:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-regulatory-barriers-for-bristol-myers-squibb-s-car-t-cell-therapies-expanding-patient-access 2025-06-27T13:13:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-removes-regulatory-barriers-for-bristol-myers-squibb-s-car-t-cell-therapies-expanding-patient-access 2025-06-27T13:13:32+00:00 hourly 0.9 https://trial.medpath.com/news/sms-pharmaceuticals-passes-second-usfda-inspection-with-zero-observations-at-telangana-analytical-laboratory 2025-06-27T13:10:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sms-pharmaceuticals-passes-second-usfda-inspection-with-zero-observations-at-telangana-analytical-laboratory 2025-06-27T13:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/perceptive-advisors-completes-7-billion-acquisition-of-crispr-solutions-leader-synthego 2025-06-27T10:28:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perceptive-advisors-completes-7-billion-acquisition-of-crispr-solutions-leader-synthego 2025-06-27T10:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/glofitamab-pirtobrutinib-combination-shows-77-response-rate-in-btk-inhibitor-exposed-mantle-cell-lymphoma 2025-06-27T09:52:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glofitamab-pirtobrutinib-combination-shows-77-response-rate-in-btk-inhibitor-exposed-mantle-cell-lymphoma 2025-06-27T09:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-medical-advances-hemopurifier-cancer-trial-with-first-three-patients-treated-and-indian-regulatory-approval 2025-06-27T08:55:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aethlon-medical-advances-hemopurifier-cancer-trial-with-first-three-patients-treated-and-indian-regulatory-approval 2025-06-27T08:55:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-streamlined-access-for-bristol-myers-squibb-car-t-cell-therapies 2025-06-27T08:55:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-streamlined-access-for-bristol-myers-squibb-car-t-cell-therapies 2025-06-27T08:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-significant-neutropenia-risk-variations-among-adc-therapies 2025-06-27T08:55:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-significant-neutropenia-risk-variations-among-adc-therapies 2025-06-27T08:55:15+00:00 hourly 0.9 https://trial.medpath.com/news/asahi-kasei-pharma-initiates-phase-iii-trial-of-art-123-for-chemotherapy-induced-peripheral-neuropathy-prevention 2025-06-27T08:12:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asahi-kasei-pharma-initiates-phase-iii-trial-of-art-123-for-chemotherapy-induced-peripheral-neuropathy-prevention 2025-06-27T08:12:03+00:00 hourly 0.9